

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	130	(548/359.1).CCLS.	US-PGP UB; USPAT; USOCR ; EPO; JPO; DERWE NT; IBM_T DB	OR	OFF	2007/07/08 11:33
L2	2078	(514/406).CCLS.	US-PGP UB; USPAT; USOCR ; EPO; JPO; DERWE NT; IBM_T DB	OR	OFF	2007/07/08 11:33
L3	25	I2 and I1	US-PGP UB; USPAT; USOCR ; EPO; JPO; DERWE NT; IBM_T DB	OR	ON	2007/07/08 11:33

10820453C>

07/08/2007

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:47:57 ON 08 JUL 2007

=> file req

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

0.21

9.21

FILE 'REGISTRY' ENTERED AT 10:48:04 ON 08 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2007 HIGHEST RN 941668-53-7
DICTIONARY FILE UPDATES: 6 JUL 2007 HIGHEST RN 941668-53-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10820453.str
```



```
chain nodes :  
19 20 21 22 23 24  
ring nodes :
```

10820453C>

07/08/2007


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
7-19 10-13 20-21 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12 13-14
13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
5-7 6-9 7-8 7-19 8-9 8-10 9-12 10-11 11-12 20-21 21-22 21-23
exact bonds :
10-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 10:48:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 39 TO ITERATE

100.0% PROCESSED 39 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10820453C>

07/08/2007

BATCH **COMPLETE**
PROJECTED ITERATIONS: 406 TO 1154
PROJECTED ANSWERS: 0 TO 0


L2 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 10:48:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 793 TO ITERATE

100.0% PROCESSED 793 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\108204532.str



chain nodes :
13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
7-13 14-15 15-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12
exact/norm bonds :
5-7 6-9 7-8 7-13 8-9 8-10 9-12 10-11 11-12 14-15 15-16 15-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom

L4 STRUCTURE UPLOADED


=> d
L4 HAS NO ANSWERS

10820453C>

07/08/2007

L4

STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 14
SAMPLE SEARCH INITIATED 10:50:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        48 TO ITERATE

100.0% PROCESSED      48 ITERATIONS .          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                      BATCH **COMPLETE**
PROJECTED ITERATIONS:      545 TO     1375
PROJECTED ANSWERS:          0 TO      0
```

L5 0 SEA SSS SAM L4

```
=> s 14 full
FULL SEARCH INITIATED 10:50:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        989 TO ITERATE


100.0% PROCESSED      989 ITERATIONS          0 ANSWERS
SEARCH TIME: 00.00.01
```

L6 0 SEA SSS FUL L4

```
=>
Uploading C:\Program Files\Stnexp\Queries\108204533.str
```

10820453C>

07/08/2007



chain nodes :

13 14 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

7-13 14-15 15-16 15-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12

exact/norm bonds :

5-7 6-9 7-8 7-13 8-9 8-10 9-12 10-11 11-12 14-15 15-16 15-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR



Structure attributes must be viewed using STN Express query preparation.


```
=> s 17
SAMPLE SEARCH INITIATED 10:52:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        48 TO ITERATE

100.0% PROCESSED      48 ITERATIONS          28 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      545 TO     1375
PROJECTED ANSWERS:         243 TO     877
```

L8 28 SEA SSS SAM L7

```
=>
Uploading C:\Program Files\Stnexp\Queries\108204534.str
```



10820453C>

07/08/2007


chain nodes :
13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 19 20 21 22 23 24
chain bonds :
7-13 10-19 14-15 15-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12 19-20
19-24 20-21 21-22 22-23 23-24
exact/norm bonds :
5-7 6-9 7-8 7-13 8-9 8-10 9-12 10-11 11-12 14-15 15-16 15-17
exact bonds :
10-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 19-20 19-24 20-21 21-22 22-23 23-24

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom

L9 STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS
L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 19
SAMPLE SEARCH INITIATED 10:53:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 39 TO ITERATE

10820453C>

07/08/2007

100.0% PROCESSED 39 ITERATIONS
SEARCH TIME: 00.00.01

19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 406 TO 1154
PROJECTED ANSWERS: 119 TO 641

L10 19 SEA SSS SAM L9

=> s 19 full
FULL SEARCH INITIATED 10:53:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 793 TO ITERATE

100.0% PROCESSED 793 ITERATIONS 358 ANSWERS
SEARCH TIME: 00.00.01

L11 358 SEA SSS FUL L9

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
SESSION
FULL ESTIMATED COST ENTRY 519.00 519.21

FILE 'CAPLUS' ENTERED AT 10:53:36 ON 08 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 6 Jul 2007 (20070706/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 111
L12 19 L11

=> d ibib abs hitstr tot

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1186413 CAPLUS

DOCUMENT NUMBER: 146:38435

TITLE: 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors

AUTHOR(S): Singh, S. K.; Dessaulew, N.; Bheratam, P. V.

CORPORATE SOURCE: Pharmacoconformatics Division, Sector 67, S.A.S.

Nager,

National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, 160062, India

SOURCE: European Journal of Medicinal Chemistry (2006), 41(11), 1310-1319

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cyclin dependent kinases (CDKs) have appeared as important drug targets over the years with diverse therapeutic potencies. With the objective of designing new chemical entities with enhanced inhibitory potencies against

CDK 2 (CDK2) and CDK 4 (CDK4), the 3D-QSAR CoMFA study carried out on indenopyrazole derivs. as inhibitors of these kinases is presented here. The developed model showed a strong correlative and predictive capability having a cross validated correlation co-efficient of 0.747 for CDK4 and 0.755 for CDK2 inhibitions. The conventional and predictive correlation co-efficients were, resp., found to be 0.913 and 0.760 for CDK4, 0.941

and 0.765 for CDK2. The models could be employed to design ligands with enhanced inhibitory potencies and/or to predict the potencies of analogs to guide synthesis.

IT 247148-81-8 247148-02-6

247149-03-1 247149-05-9 247149-07-1

360792-67-2 360792-68-3 360792-69-4

360792-70-7 360792-71-8 360792-72-9

360792-73-0 360792-77-4 360792-78-5

360792-84-3 360792-85-4 360792-86-5

360792-87-6 360792-88-7 360792-90-1

360792-91-2 364733-05-7 478162-12-8

499448-91-1 499448-92-2 499448-93-3

807628-55-3 807628-56-4 807628-57-5

807628-58-6 807628-60-0 916593-24-3

916593-25-4

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

3D-QSAR CoMFA study on indenopyrazole derivs. as CDK4 and CDK2 inhibitors


RN 247148-81-8 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-

N'-phenyl- (CA INDEX NAME)


L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)



RN 247149-05-9 CAPLUS


CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)



RN 247149-07-1 CAPLUS


CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247148-84-1 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 247149-02-6 CAPLUS


CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (CA INDEX NAME)



RN 247149-03-7 CAPLUS


CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-67-2 CAPLUS


CN Benzoic acid, 3,5-dimethoxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-68-3 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-69-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-70-7 CAPLUS
CN Benzoic acid, 3,4-dihydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-71-8 CAPLUS
CN Benzoic acid, 4-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-72-9 CAPLUS
CN Benzoic acid, 3-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-73-0 CAPLUS
CN Benzoic acid, 4-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-77-4 CAPLUS
CN Benzoic acid, 2-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)


L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-78-5 CAPLUS
CN Benzoic acid, 3,5-diamino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-84-3 CAPLUS
CN 2-Naphthalene carboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-85-4 CAPLUS
CN Benzenepropanoic acid, 4-hydroxy-,
2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 360792-86-5 CAPLUS
CN Benzoic acid, 4-methoxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-87-6 CAPLUS
CN Benzoic acid, 3-nitro-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-88-7 CAPLUS
CN Benzoic acid, 3,4,5-trimethoxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)



RN 360792-91-2 CAPLUS
CN Benzoic acid, 2,5-dichloro-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-90-1 CAPLUS
CN Benzoic acid, 3-methyl-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-
oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 364733-85-7 CAPLUS
CN Urea, N-butyl-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-
c]pyrazol-5-yl)- (CA INDEX NAME)


L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478162-12-8 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(phenylmethyl) - (CA INDEX NAME)




RN 489448-91-1 CAPLUS
CN Benzoic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl)hydrazide (CA INDEX NAME)




RN 489448-92-2 CAPLUS
CN Benzenoacetic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)


L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 489448-93-3 CAPLUS
CN Hydrazinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl-, methyl ester (CA INDEX NAME)




RN 807628-55-3 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide [CA INDEX NAME]




RN 807628-56-4 CAPLUS
CN Benzoic acid, 3-amino-4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxindeno[1,2-c]pyrazol-5-ylamino)carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 807628-57-5 CAPLUS
CN Benzoic acid, 2,4-dihydroxy-, 2-((2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino)carbonyl)hydrazide (CA INDEX NAME)




RN 807628-58-6 CAPLUS
CN Acetic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)


L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 807628-60-0 CAPLUS
CN Acetic acid, 2-amino-2-oxo-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl)hydrazide (CA INDEX NAME)



RN 916593-24-3 CAPLUS
CN Urea, N-[2-(4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-1-piperidinyl] (CA INDEX NAME)




RN 916593-25-4 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N-(1-methyl-1H-indole-3-yl)- (CA INDEX: NAME).

10820453C>

07/08/2007

L12 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:3175115 CAPLUS

146:311809

TITLE: MASPIIT: Three-Hybrid Trap for Quantitative Proteome Fingerprinting of Small Molecule-Protein Interactions in Mammalian Cells

AUTHOR(S): Caliguri, Maureen; Molz, Lisa; Liu, Qing; Kaplan, Faith; Xu, Jimmy P.; Majeti, Jiangwen Z.; Ramos-Kelley, Rebecca; Murthi, Krishna; Lievens, Sam; Tavernier, Jan; Kley, Nikolai

CORPORATE SOURCE: GPC Biotech Incorporated, Waltham, MA, 02451, USA SOURCE: Chemistry & Biology (Cambridge, MA, United States) (2006), 13(7), 711-722

CODEN: CBIOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Organic small mols. generally act by perturbing the function of one or more cellular target proteins, the identification of which is essential to an understanding of the mol. basis of drug action. Here the authors

describe the application of methotrexate-linked small mol. ligands to a mammalian three-hybrid interaction trap for proteome-wide identification of small mol. targets, quantification of the targeting potency of unmodified small mols. for such targets in intact cells, and screening for inhibitors of small mol.-protein interactions. During the course of this study the authors also identified the pyrido[2,3-d]pyrimidine PD173955, a known SRC kinase inhibitor, as a potent inhibitor of several ephrin receptor tyrosine kinases. This finding could perhaps be exploited in the design of inhibitors for this kinase subfamily, members of which have been implicated in the pathogenesis of various diseases, including cancer.

IT 929023-64-3, RGB 285978 929023-65-4, RGB 286298
RL ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)


(MASPIIT in relation to three-hybrid trap for quant. proteome fingerprinting of small mol.-protein interactions in mammalian cells)

RN 929023-64-3 CAPLUS

CN Urea, N-[2-(4-dihydro-3-[4-(2-(4-(1-methylethyl)-1-


piperazinyl)ethyl]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)

L12 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 929023-65-4 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[2-[(4S)-4-carboxy-4-[[4-[(2,4-diamino-6-pteridinyl)methyl]methylenobenzoyl]amino]1-oxobutyl]amino]ethyl]-α-[2-[(4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl)ethyl]-1-piperazinyl]acetyl]aminoethoxy- (CA INDEX NAME)

PAGE 1-A




L12 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:13464 CAPLUS

DOCUMENT NUMBER: 144:101073

TITLE: therapeutic uses of kinase inhibitors, and

compositions thereof

INVENTOR(S): Caliguri, Maureen G.; Kley, Nikolai A.; Murthi,

Krishna K.

PATENT ASSIGNEE(S): GPC Biotech, Inc., USA

SOURCE: PCT Int. Appl., 201 pp.

CODEN: PIXDZ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002119	A2	20060105	WO 2005-US21843	20050617
WO 2006002119	A3	20070321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, C2, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2584493	A1	20060105	CA 2005-2584493	20050617
EP 1763345	A2	20070321	EP 2005-762059	20050617
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.: US 2004-580868P	P	20040618		
	WO 2005-US21843	W	20050617	

OTHER SOURCE(S): MARPAT 144:101073

AB The invention pertains to inhibitors of various kinases (e.g. S/T

kinases,


Tyr kinases, etc.). Which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). The inhibitors of the invention are capable of inhibiting various wild-type and mutant form kinases, including drug-resistant forms of mutant kinases. Thus, the kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal functions/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractory to other therapeutic agents. Pharmaceutical compns. and packaged pharmaceuticals with instructions of these inhibitors, and methods of using these inhibitors are also provided.

IT 784210-86-2P 784211-90-1P

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Kinase inhibitors for therapeutic use)
 RN 784210-86-2 CAPLUS
 CN Piperazine, 1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 784211-90-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(4-(2-methoxyethyl)-1-piperazinyl)methyl]phenyl]-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl

IT 516494-06-7 516494-08-9 516494-11-4

516494-13-6 516494-14-7 516494-16-9

516494-18-1 516494-20-5 516494-22-7

516494-24-9 516494-26-1 784211-18-3

784211-19-4 784211-20-7 784211-21-8

784211-22-2 784211-23-0 784211-24-1

784211-25-2 784211-29-6 784211-31-0

784211-32-1 784211-33-2 784211-34-3

784211-35-4 784211-37-6 784211-39-8

784211-40-1 784211-44-5 784211-45-6

784211-46-7 784211-47-8 784211-49-0

784211-50-3 784211-51-4 784211-52-5

784211-53-7 784211-57-0 784211-58-1

784211-59-2 784211-88-7 784211-89-8

784211-91-2 784211-92-3 784211-93-4

784211-94-5 784211-95-6 784211-97-8

808742-08-7 808742-13-4 808742-83-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Kinase inhibitors for therapeutic use)

RN 516494-06-7 CAPLUS


CN Urea,

N-[2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI)

(CA INDEX NAME)


L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



● 3 HCl

RN 516494-08-9 CAPLUS
 CN Urea, N-[3-[4-[(cyclopropylmethyl)propylamino]ethoxy]phenyl]-2,4-dihydro-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 516494-11-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-(1-pyrrolidinyl) .. .]

Page 15

10820453C>


07/08/2007

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-(c)pyrazol-5-yl)-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 516494-13-6 CAPLUS
CN Urea,
N-(2,4-dihydro-4-oxo-3-[4-(phosphonoxy)phenyl]indeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 516494-14-7 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●4 HCl

RN 516494-16-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

●3 HCl

RN 516494-18-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 516494-20-5 CAPLUS
CN Urea, N-[3-(4-[2-(bis(2-hydroxyethyl)amino)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



●2 HCl

RN 516494-22-7 CAPLUS
CN Urea,
N-[2,4-dihydro-3-[4-[(2S)-3-hydroxy-1-pyrrolidinyl]ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 516494-24-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[(1-pyrrolidinyl)ethoxy]phenyl]-4-


Page 16

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A

● 2 HCl

● 3 HCl


RN 516494-26-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 3 HCl

RN 784211-19-4 CAPLUS
 CN Urea, N-[3-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-20-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)


SAEED

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 784211-21-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(4-morpholinyl)ethoxy)phenyl]-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 784211-22-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1-piperidinyl)ethoxy)phenyl]-4-

Page 17

10820453C>

07/08/2007

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A

●3 HCl

RN 784211-23-0 CAPLUS
CN Urea, N-[3-[4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

●4 HCl

RN 784211-24-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-(4-morpholinylmethyl)phenyl]-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl


RN 784211-25-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 784211-31-0 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(2-(1H-pyrazol-1-yl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



PAGE 2-A

●2 HCl

RN 784211-29-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-




●2 HCl

RN 784211-32-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(4-(1-methylethyl)-1-

SAEED

Page 18

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 piperazinyl]ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

RN 784211-33-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(4-(1-methylethyl)-1-piperazinyl]ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

● 4 HCl


RN 784211-34-3 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(3-[4-(1-methylethyl)-1-piperazinyl]propoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-morpholinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl

RN 784211-35-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-(4-(1-methylethyl)-1-piperazinyl)propoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-37-6 CAPLUS
 CN Urea, N-(2,4-dihydro-4-oxo-3-[2-(1-pyrrolidinyl)ethoxyphenyl]indeno[1,2-c]pyrazol-5-yl)-N'-(4-(1-methylethyl)-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



● 2 HCl

RN 784211-39-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(1-pyrrolidinyl)ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-40-1 CAPLUS
 1-Piperazineacetic acid, 4-[[[2,4-dihydro-4-oxo-3-[4-[2-(1-

10820453C>

07/08/2007

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrrolidinylmethoxyphenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino]-
ethyl ester, trihydrochloride (9CI) (CA INDEX NAME)




RN 784211-44-5 CAPLUS
CN Urea, N-[2,4-dihydro-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-
oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI)
(CA INDEX NAME)

PAGE 2-A

●3 HCl


L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

RN 784211-45-6 CAPLUS
CN L-Valine, 2-[4-[[2,4-dihydro-4-oxo-3-(4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino]-
1-piperazinyl]ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.

PAGE 1-A




●2 HCl

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 784211-46-7 CAPLUS
CN Acetamide, 2-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-
oxoindeno[1,2-c]pyrazol-3-yl]phenoxy-N,N-dimethyl- (9CI) (CA INDEX
NAME)

PAGE 1-B




RN 784211-47-8 CAPLUS
CN Urea,
N-[2,4-dihydro-3-[4-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-
4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 784211-49-0 CAPLUS
CN 1-Piperazineacetic acid, 4-[[[2,4-dihydro-4-oxo-3-[4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino]-
1-methylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

RN 784211-50-3 CAPLUS
CN 1-Piperazineacetamide, 4-[[[2,4-dihydro-4-oxo-3-[4-[2-(1-
pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyra


Page 20

SAEED

10820453C>


07/08/2007

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

PAGE 2-A

● 2 HCl



RN 784211-51-4 CAPLUS
CN Pyrrolidine, 1-[(4-(2,4-dihydro-5-[[[(4-methyl-1-piperazinyl)amino]carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 784211-52-5 CAPLUS

CN Urea,
N-(2,4-dihydro-3-[(4-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L12 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





● 2 HCl

PAGE 2-A

● HCl

RN 784211-53-6 CAPLUS
CN Pyrrolidine,
1-[(4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)


RN 784211-58-1 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl)sulfonyl]-4-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-57-0 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

RN 784211-59-2 CAPLUS
CN Acetic acid, [4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 784211-88-7 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-89-8 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 784211-91-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 784211-92-3 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

methoxyethylphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 784211-93-4 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[(2-(methylsulfonyl)ethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 784211-94-5 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-

methoxyethylphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-95-6 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 784211-97-8 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 808742-08-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(3-methyl-4-[2-(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 808742-13-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 808742-83-8 CAPLUS
 CN L-Valine, 2-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl)methyl]aminoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 452913-27-8P 784210-85-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Kinase inhibitors for therapeutic use)
 RN 452913-27-8 CAPLUS
 CN Acetic acid, 4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-ylphenoxy- (9CI) (CA INDEX NAME)



RN 784210-85-1 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2005:612300 CAPLUS
 DOCUMENT NUMBER: 143:109828

TITLE: Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur F.; Oalmann, Chris;

Murthi, Krishna K.; Ram, Siya; Wang, Zhongguo; Huang, Jianxing

PATENT ASSIGNEE(S): GPC Biotech, Inc., USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXX2D

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063765	A1	20050714	WO 2004-US43492	20041221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NL, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004309415	A1	20050714	AU 2004-309415	20041221
CA 2551640	A1	20050714	CA 2004-2551640	20041221
EP 1709051	A1	20061011	EP 2004-815554	20041221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1922180	A	20070228	CN 2004-80042035	20041221
BR 2004018095	A	20070417	BR 2004-18095	20041221
JP 2007516296	T	20070621	JP 2006-547427	20041221
NO 2006003186	A	20060920	NO 2006-3186	20060710
IN 2006DN04222	A	20070622	IN 2006-DN422	20060721
PRIORITY APPLN. INFO.:			US 2003-531872P	P 20031223
			US 2004-560138P	P 20040406
			US 2004-616480P	P 20041006
			WO 2004-US43492	W 20041221

OTHER SOURCE(S): MARPAT 143:109828
 GI




AB The invention pertains to novel cyclin dependent kinase inhibitors (cdk's) of formula (I) where R8 represents a substituted or unsubstituted heterocycle; F represents (CH₂)_n, where n is an integer between 1 and 6; and Q represents a substituted or unsubstituted secondary amino substituent, or substituted or unsubstituted tertiary amino substituent, or substituted or unsubstituted nitrogen-containing heterocycle and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. would be useful for treating subjects having disorders associated with excessive cell proliferation.

IT
 516494-04-5 516494-06-7 516494-08-9
 516494-11-4 516494-13-6 516494-14-7
 516494-16-9 516494-18-1 516494-20-5
 516494-22-7 516494-24-9 516494-26-1
 784211-86-2 784211-19-4 784211-20-7
 784211-21-8 784211-22-9 784211-23-0
 784211-24-1 784211-25-2 784211-29-6
 784211-31-0 784211-32-1 784211-33-2
 784211-34-3 784211-35-4 784211-37-6
 784211-39-8 784211-40-1 784211-44-9
 784211-45-6 784211-46-7 784211-47-8
 784211-48-9 784211-49-0 784211-50-1
 784211-51-4 784211-52-5 784211-53-6
 784211-57-0 784211-58-1 784211-59-2
 784211-88-7 784211-89-8 784211-90-1
 784211-91-2 784211-92-3 784211-93-4
 784211-94-5 784211-95-6 784211-97-0
 808742-04-3 808742-05-4 808742-06-5
 808742-07-6 808742-08-7 808742-13-4
 808742-83-8 808750-10-9

RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses); inhibitors of cyclin-dependent kinases, compns. and uses to modulate cell-cycle modulation and control cell growth and differentiation)


RN 516494-04-5 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-(2-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 516494-06-7 CAPLUS
CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 3 HCl


RN 516494-08-9 CAPLUS
CN Urea, N-[3-[4-[2-(cyclopropylmethyl)propylamino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 516494-11-4 CAPLUS
CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 2-B



● 3 HCl

RN 516494-13-6 CAPLUS
CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-(phosphonoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, (9CI) (CA INDEX NAME)




RN 516494-14-7 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

10820453C>

07/08/2007


L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 4 HCl

RN 516494-16-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(2-methyl)-4-(2-(1-pyrrolidinyl)ethoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 3 HCl


RN 516494-18-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-[2-((2S)-2-(hydroxymethyl)-1-pyrrolidinyl)ethoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 516494-22-7 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[2-((3S)-3-hydroxy-1-pyrrolidinyl)ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl


RN 516494-24-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(3-methyl-4-(2-(1-pyrrolidinyl)ethoxyphenyl)-4-

SAEED

Page 25

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


● 3 HCl

RN 516494-26-1 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-(4-[2-(4-morpholinyl)ethoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784210-86-2 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]-4-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-19-4 CAPLUS
 CN Urea, N-[3-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-20-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-(4-morpholinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-21-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-23-0 CAPLUS
 CN Urea, N-[3-[4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

RN 784211-24-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-hydroxy-3-(4-morpholinylmethyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-25-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1H-pyrazol-1-yl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl



RN 784211-29-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 784211-31-0 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


● 2 HCl

RN 784211-32-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-(2-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 784211-33-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



PAGE 2-A


● 4 HCl

RN 784211-34-3 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[3-(4-(1-methylethyl)-1-piperazinyl)propoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-35-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 784211-37-6 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-[4-(1-methylethyl)-1-piperazinyl]-, dihydrochloride




PAGE 2-A

● 2 HCl

RN 784211-39-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



● 3 HCl

RN 784211-44-5 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 784211-45-6 CAPLUS
 CN L-Valine, 2-[4-((2,4-dihydro-4-oxo-3-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)indeno[1,2-c]pyrazol-5-yl)amino)carbonyl]amino)-1-piperazinyl ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



●2 HCl




RN 784211-48-9 CAPLUS
 CN Morpholine, 4-[(4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl- (9CI) (CA INDEX NAME)




RN 784211-49-0 CAPLUS
 CN 1-Piperazineacetic acid, 4-((2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl)amino)carbonyl)amino)-1-methyl ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-B




RN 784211-46-7 CAPLUS
 CN Acetamide, 2-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 784211-47-8 CAPLUS
 CN Urea,
 N-(2,4-dihydro-3-(4-((3-methyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

PAGE 1-A




●2 HCl

RN 784211-50-3 CAPLUS
 CN 1-Piperazineacetamide, 4-((2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl)amino)carbonyl)amino)-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



PAGE 1-A

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



PAGE 1-A

PAGE 2-A

● HCl

● 2 HCl

RN 784211-51-4 CAPLUS


CN Pyrrolidine, 1-[(4-[2,4-dihydro-5-[(4-methyl-1-piperazinyl)amino]carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 784211-52-5 CAPLUS

CN Urea,
N-(2,4-dihydro-3-(4-((3-methyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



PAGE 1-A

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



● 2 HCl

RN 784211-58-1 CAPLUS

CN Piperazine, 1-[(4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]sulfonyl]-4-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-59-2 CAPLUS

CN Acetic acid, (4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy)-, ethyl ester (9CI) (CA INDEX NAME)

RN 784211-53-6 CAPLUS


CN Pyrrolidine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl-, (9CI) (CA INDEX NAME)




RN 784211-57-0 CAPLUS

CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 784211-88-7 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 784211-89-8 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 HCl

RN 784211-90-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-91-2 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[(1-methylethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)


● 2 HCl

RN 784211-92-3 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-93-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[(2-(methylsulfonyl)ethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

● HCl

RN 784211-94-5 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-95-6 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)


10820453C>

07/08/2007

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 784211-97-8 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl-, monohydrochloride (9CI)
(CA INDEX NAME)




RN 808742-04-3 CAPLUS
CN Urea, N-[3-(2-fluoro-4-[(1-pyrrolidinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



RN 808742-05-4 CAPLUS
CN Urea, N-[3-(2-fluoro-4-[(2-(4-methyl-1-piperazinyl)ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A


● 2 HCl

● HCl


RN 808742-04-3 CAPLUS
CN Urea, N-[3-(2-fluoro-4-[(1-pyrrolidinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A




RN 808742-06-5 CAPLUS
CN Urea, N-[3-(2-fluoro-4-[(2-(1-pyrrolidinyl)ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 808742-07-6 CAPLUS
CN Urea, N-[3-(2-fluoro-4-[(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-,



RN 808742-08-7 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(2-(4-(1-methylethyl)-1-piperazinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 808742-13-4 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(2-methyl-4-[(1-pyrrolidinyl)ethoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

SAEED

Page 32


L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl


RN 808742-83-8 CAPLUS
 CN L-Valine, 2-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxindeno[1,2-c]pyrazol-3-yl]phenyl]methylaminoethyl ester (HCl) (CA INDEX NAME)

Absolute stereochemistry.



RN 808750-10-9 CAPLUS
 CN Urea
 N-[3-[3-fluoro-4-(2-[4-(1-methylethyl)-1-piperazinyl]ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-triethylchloride (HCl) (CA INDEX NAME)

L12 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:2193 CAPLUS
 DOCUMENT NUMBER: 142:51353
 TITLE: Pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents
 INVENTOR(S): Becker, Frank; Bockovich, Nicholas; Come, Jon H.; Kluge, Arthur; Murthi, Krishna K.; Oelmann, Chris; Ram, Siya; Wang, Zhongguo
 PATENT ASSIGNEE(S): GPC Biotech, Inc., USA; GPC Biotech A.-G.
 SOURCE: U.S. Pat. Appl. Publ., 103 pp., Cont.-in-part of Appl.

No. PCT/US02/33052.

CODEN: USXKCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004266854	A1	20041230	US 2004-820453	20040407
WO 2002070662	A2	20020912	WO 2002-U56677	20020304
WO 2002070662	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003165873	A1	20030904	US 2002-91177	20020304
US 200404338B	A1	20040304	US 2002-234985	20020903
US 7135550	B2	20061114		
WO 2003033499	A2	20030424	WO 2002-U533052	20021015
WO 2003033499	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2001-272932P	P	20010302		
	US 2001-329437P	P	20011015	
	US 2001-336962P	P	20011203	
	US 2002-91177	A2	20020304	
	WO 2002-U56677	A2	20020304	
	US 2002-234985	A2	20020903	
	WO 2002-U533052	A2	20021015	

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 2003-460921P P 20030407


US 2003-531872P P 20031223

US 2001-278233P P 20010323

OTHER SOURCE(S): MARPAT 142:51353
GI


AB Title compds. I [B = MnR8; Ar = aryl, heteroaryl; V = O, S, NCN; W = O, S, N-R'; R' = H, lower alkyl, metal counterion; R5 = H, P(O)(OR')2, MnQ; R6 = H, OH, MnQ, provided that one and only one of R5 and R6 = H; R7 = H, halo, OH, lower alkyl, lower alkoxy; R8 = (un)substituted-alkyl, -alkenyl, -aryl, etc.; M = (un)substituted methylene, O, S, etc., where n = 1-4 when present in B, or 6 when present in R5, and 1-3 when present in R6; Q = (un)substituted tertiary amino substituent, N-containing heterocycle] and II [X = Me, halo; Y = H, X, sulfonamide; R1 = H, P(O)(OR')2, MnQ; R3 = O-3-substituents on the ring to which it is attached, selected from halo, alkyl, alkoxy, etc.; Ar and W as in I], as well as their pharmaceutically acceptable salts, are prepared and disclosed as novel cyclin dependent kinase (cdk) inhibitors. Thus, e.g., III·2HCl was prepared via substitution of N-morpholin-4-yl(4-nitrophenoxy)carboxamide (preparation given) with 4-amino-2-(4-(5,5-dimethyl-1,3-dioxan-2-yl)phenylcarbonyl)-2H-cyclopent-1[2-a]benzene-1,3-dione (preparation given) followed by cyclocondensation with hydrazine, deprotection of formyl moiety, amidation with N-(2-methoxyethyl)-piperazine and subsequent reduction. Specifically, but not exclusively, I are disclosed as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. would be useful for treating subjects having disorders associated with excessive cell proliferation, such as

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 cancer. Addnl., the compds. may be useful as antivirals.
 IT 516493-95-1P 784210-86-2P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (pyrazole derivative inhibitors of cyclin-dependent kinases for use as
 antitumor and antiviral agents)
 RN 516493-95-1 CAPLUS
 CN Urea, N-[3-{4-[2-(cyclopropylmethyl)propylamino]ethoxy}phenyl]-2,4-
 dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl- (9CI) (CA
 INDEX NAME)



RN 784210-86-2 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-
 oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl)-4-(1-methylethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

IT 516494-06-7 516494-11-4 516494-13-6
 516494-14-7 516494-16-9 516494-18-1
 516494-20-5 516494-22-7 516494-24-9
 516494-26-1 784211-18-3 784211-19-4
 784211-20-7 784211-21-1 784211-22-9
 784211-23-4 784211-24-1 784211-25-2
 784211-29-9 784211-31-1 784211-32-1
 784211-33-2 784211-34-3 784211-35-4
 784211-37-6 784211-44-5 784211-45-6
 784211-46-7 784211-47-7 784211-48-9
 784211-49-7 784211-51-7 784211-52-5
 784211-53-6 784211-57-7 784211-58-1
 784211-59-2 784211-88-7 784211-89-0
 784211-91-2 784211-92-3 784211-93-4
 784211-94-5 784211-95-3 784211-97-8
 808742-04-3 808742-05-4 808742-06-5
 808742-07-6 808742-08-7 808742-09-8
 808742-10-1 808742-11-2 808742-12-3
 808742-13-4 808742-14-5 808742-15-6
 808742-16-7 808742-17-8 808742-24-7
 808742-26-9 808742-28-1 808742-30-5
 808742-32-7 808742-34-9 808742-37-2
 808742-39-4 808742-41-9 808742-43-0
 808742-45-2 808742-47-4 808742-49-6
 808742-52-1 808742-55-4 808742-57-6
 808742-59-8 808742-61-2 808742-63-4
 808742-65-6 808742-67-8 808742-69-0
 808742-71-4 808742-73-6 808742-75-8
 808742-83-8 808742-86-1 808750-10-9
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pyrazole derivative inhibitors of cyclin-dependent kinases for use as

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 antitumor and antiviral agents)
 RN 516494-06-7 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}indeno[1,
 2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 3 HCl


RN 516494-11-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}indeno[1,
 2-c]pyrazol-5-yl]-N'-(4-morpholinyl)-, trihydrochloride (9CI) (CA INDEX
 NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 3 HCl

IT 516494-13-6 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-{4-(phosphonoxy)phenyl}indeno[1,2-c]pyrazol-
 5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 516494-14-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-{4-hydroxy-3-[(4-(1-methylethyl)-1-
 piperazinyl)methyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-
 morpholinyl-, tetrahydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 4 HCl

RN 516494-16-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

● 3 HCl

RN 516494-18-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 516494-20-5 CAPLUS
CN Urea, N-[3-[4-(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 2-A


PAGE 1-A



● 3 HCl

RN 516494-22-7 CAPLUS
CN Urea,
N-[2,4-dihydro-3-[4-(2-(3S)-3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl


RN 516494-24-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[3-methyl-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-

SAEED




● 2 HCl

RN 784211-18-3 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[2-(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-19-4 CAPLUS
CN Urea, N-[3-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-20-7 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-21-8 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 784211-22-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(1-piperidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 784211-23-0 CAPLUS
CN Urea, N-[3-[4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

● 3 HCl




● 4 HCl

RN 784211-24-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-(4-morpholinylmethyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-25-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(1H-pyrazol-1-yl)ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 784211-29-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 784211-31-0 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(2-(1H-pyrazol-1-yl)ethoxyphenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


● 2 HCl


RN 784211-32-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 784211-33-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-[4-(1-methylethyl)-1-piperazinyl]ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)






● 4 HCl

RN 784211-34-3 CAPLUS
 CN Urea, N-(2,4-dihydro-3-[4-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-35-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 784211-37-6 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-(1-methylethyl)-1-piperazinyl)-, dihydrochloride




● 2 HCl


RN 784211-44-5 CAPLUS
 CN Urea, N-(2,4-dihydro-3-[3-methoxy-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

RN 784211-45-6 CAPLUS
 CN L-Valine, 2-[4-[(2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino)-1-piperazinyl]ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl




● 2 HCl




RN 784211-46-7 CAPLUS
 CN Acetamide, 2-[4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 784211-47-8 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[(4-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 784211-48-9 CAPLUS
 CN Morpholine, 4-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl- (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 784211-49-0 CAPLUS
 CN 1-Piperazineacetic acid, 4-[[[(2,4-dihydro-4-oxo-3-(4-[2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino]-1-methylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 784211-51-4 CAPLUS
 CN Pyrrolidine, 1-[(4-[2,4-dihydro-5-[(4-methyl-1-piperazinyl)amino]carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 784211-52-5 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[(4-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A

● HCl

RN 784211-53-6 CAPLUS
 CN Pyrrolidine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl- (9CI) (CA INDEX NAME)




RN 784211-57-0 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 784211-58-1 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenyl]sulfonyl]-4-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 784211-59-2 CAPLUS
 CN Acetic acid, [4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




●2 HCl

RN 784211-91-2 CAPLUS
 CN Urea, N-(2,4-dihydro-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 784211-92-3 CAPLUS
 CN Urea, N-(2,4-dihydro-3-[(4-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]ethyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 784211-68-7 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[(4-((4-pyridinyl)-1-piperazinyl)methyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 784211-69-8 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[(4-(2-pyrimidinyl)-1-piperazinyl)methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-93-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[(4-[(2-methylsulfonyl)ethyl]amino)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-94-5 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[(4-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-95-6 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 784211-97-8 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 808742-04-3 CAPLUS
 CN Urea, N-[3-(2-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 808742-05-4 CAPLUS
 CN Urea, N-[3-(2-fluoro-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A

● 3 HCl


RN 808742-06-5 CAPLUS
 CN Urea, N-[3-(3-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



RN 808742-07-6 CAPLUS

CN Urea,
 N-[3-(2-fluoro-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 808742-08-7 CAPLUS


CN Urea, N-[2,4-dihydro-3-(3-methyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl


RN 808742-09-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI)
 (CA INDEX NAME)



● 2 HCl


RN 808742-10-1 CAPLUS
 CN 1-Piperazineacetic acid, 4-[(4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl)amino]carbonyl]amino)-

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 808742-12-3 CAPLUS
 CN Urea, N-[3-[2-chloro-4-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl

RN 808742-13-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI)
 (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 , ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● 2 HCl

RN 808742-11-2 CAPLUS
 CN Urea, N-[3-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI)
 (CA INDEX NAME)


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl

RN 808742-14-5 CAPLUS
 CN Urea,
 N-(2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl)-N'-(4-(2-(dimethylamino)oxy)-2-oxoethyl)-1-piperazinyl-,
 dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


● 2 HCl

RN 808742-15-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(4-morpholinylmethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 808742-16-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 808742-17-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(1-pyrrolidinylmethyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 808742-24-7 CAPLUS
 CN Urea, N-[3-[4-[(3-(aminomethyl)-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX)




RN 808742-26-9 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(3-[(propylamino)methyl]-1,2,4-oxadiazol-5-yl)methoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 808742-30-5 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(3-[(methylamino)methyl]-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 808742-28-1 CAPLUS
 CN Urea, N-[3-[4-[(3-[(dimethylamino)methyl]-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 808742-34-9 CAPLUS
CN Acetamide, 2-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 808742-37-2 CAPLUS
CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 808742-39-4 CAPLUS
CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 808742-41-8 CAPLUS
CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 808742-43-0 CAPLUS
CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 808742-45-2 CAPLUS
CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 808742-47-4 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(4-(2-pyridinyl)-1-piperazinyl)methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 808742-49-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 808742-52-1 CAPLUS
CN Urea, N-[3-[(bis(2-hydroxyethyl)amino)methyl]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 808742-55-4 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(4-(2-hydroxyethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 808742-57-6 CAPLUS
CN Urea, N-(2,4-dihydro-3-[(2-(2-hydroxyethoxy)ethyl)amino)methyl]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 808742-59-8 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(4-hydroxy-1-piperidinyl)methyl]phenyl]-4-


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 808742-61-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 808742-63-4 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[(4-[(3-(trifluoromethyl)phenyl)-1-piperazinyl]methyl)phenyl]indeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 808742-65-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(3R)-3-hydroxy-1-pyrrolidinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl-N'-4-morpholinyl-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 808742-67-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenyl]methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 808742-69-0 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[(2-hydroxyethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 808742-71-4 CAPLUS
 CN Urea, N-[3-[4-[(2,3-dihydroxypropyl)amino]methyl]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 808742-73-6 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(3-pyridinylmethyl)amino]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 808742-75-8 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[(2-pyridinylmethyl)amino]methyl]phenyl]-4-




● HCl

RN 808742-83-8 CAPLUS
 CN L-Valine, 2-[[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 808742-86-1 CAPLUS
 CN Acetamide, 2-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-N-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



—OMe
 RN 808750-10-9 CAPLUS
 CN Urea, N-[3-[3-fluoro-4-(2-[(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 3 HCl

IT 452913-27-8P 452913-28-9P 452913-29-0P
 452913-30-3P 452913-31-4P 452913-35-8P
 452913-36-9P 452913-37-0P 452913-38-1P
 516493-91-7P 784210-85-1P 808742-02-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents)

RN 452913-27-8 CAPLUS

CN Acetic acid, [4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-


-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 452913-28-9 CAPLUS

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 452913-30-3 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazacicosan-20-oic acid, 19-[(4-[(2,4-diamino-6-pteridinyl)methyl]methoxy)benzoyl]amino]-1-[4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 6,9,12-Trioxa-3,15-diazacicosan-20-oic acid, 1-[(4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 452913-29-0 CAPLUS
 CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 1-[(4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)-25-[(4-(methylamino)benzoyl)amino]-2,22-dioxo-, 1,1-dimethylethyl ester, (25S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 452913-31-4 CAPLUS
 CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 25-[(4-[(2,4-diamino-6-pteridinyl)methyl]methoxy)benzoyl]amino]-1-[(4-


10820453C>

07/08/2007


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,22-dioxo-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-C




RN 452913-35-8 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 452913-36-9 CAPLUS
CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 452913-37-0 CAPLUS
CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 452913-38-1 CAPLUS
CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 1-[(3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 516493-91-7 CAPLUS
CN Urea, N-[3-(4-(2-chloroethoxy)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 784210-85-1 CAPLUS
 CN Piperazine, 1-[{4-[{2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino}-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy}acetyl]-4-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




RN 808742-02-1 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaheneicosan-21-oic acid, 19-[{4-[{2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl]amino]-1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 454221-46-6 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[{4-[{2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl]amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,16-dioxo-, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



IT 454221-46-6P 454221-47-7P 808742-03-2P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents)

L12 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-C




RN 454221-47-7 CAPLUS
 CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 25-[{4-[{2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl]amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,22-dioxo-, (25S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 808742-03-2 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaheneicosan-21-oic acid, 19-[{[4-[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl}amino]-1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-2,16-dioxo-, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2004:902355 CAPLUS
 DOCUMENT NUMBER: 141:395546
 TITLE: Preparation of pyrazole derivatives as inhibitors of cyclin-dependent kinases, compositions and uses related thereto
 INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur; Oalmann, Chris; Murthi, Krishna; Ram, Siya; Wang, Zhongguo; Huang, Jianxing
 PATENT ASSIGNEE(S): GPC Biotech, Inc., USA
 SOURCE: PCT Int. Appl., 172 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092139	A2	20041028	W 2004-US10381	20040406
WO 2004092139	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MR, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TV, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, QQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230867	A1	20041028	AU 2004-230867	20040406
CA 2521854	A1	20041028	CA 2004-2521854	20040406
US 2004266853	A1	20041230	US 2004-819899	20040406
EP 1611136	A2	20060104	EP 2004-759113	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1798748	A	20060705	CN 2004-80015519	20040406
JP 2006522152	T	20060928	JP 2006-509686	20040406
NO 2005005195	A	20051104	NO 2005-5195	20051104
PRIORITY APPLN. INFO.:			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223
OTHER SOURCE(S):	MARPAT 141:395546		WO 2004-US10381	W 20040406
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I {B = MnR8; Ar = aryl or heteroaryl ring; V = O, S, or NCN;
 W = O, S, SO2, CO, CS, CH2, NH, or N-alkyl; R5 = H, P(O)(OR')2, MnJK, MnQ;
 R' = H, alkyl, or metal counterion; R6 = H, OH, or MnQ, provided that one

SAEED


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 and only one of R5 and R6 = H; R7 = H, halo, OH, alkyl, or alkoxy; R8 = (un)substituted-alkyl, -alkenyl, -aryl, etc.; J = CO, CS, or SO2; K = OR', NH, N-alkyl, etc.; M = (un)substituted methylene group, O, S, etc., where n = 1-7 when present in B, 0-6 when present in R5, and 1-3 when present in R6; Q = (un)substituted N-contg. heteroaryl ring, secondary or tertiary amino substituent, or N-contg. heterocycle; and II [X = Me or halo; Y = H, X, or sulfonamide; R1 = H, P(O)(OR')2, or MnQ; R3 = O-3 substituents on the ring to which it is attached, selected from halo, alkyl, alkoxy, etc.], as well as their pharmaceutically acceptable salts, are prep'd. and disclosed as novel cyclin dependent kinase inhibitors (cdkis). Thus, e.g., III·2HCl was prep'd. via substitution of N-morpholin-4-yl-4-nitrophenoxy)carboxamide (prep'n, given) with 4-amino-2-[(4-(5,5-dimethyl-1,3-dioxan-2-yl)phenyl)carbonyl]-2H-cyclopenta[1,2-b]benzene-1,3-dione (prep'n, given) followed by cyclocondensation with hydrazine, deprotection of formyl moiety, amidation with N-(2-methoxyethyl)-piperazine and subsequent redn. Specifically, but not exclusively, I are disclosed as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. would be useful for treating subjects having disorders assoc'd. with excessive cell proliferation.

IT 452913-27-8P 516493-91-7P 784210-85-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); TH (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyrazole derivs. as inhibitors of cyclin-dependent kinases)

RN 452913-27-8 CAPLUS


CN Acetic acid, [4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 516493-91-7 CAPLUS
 CN Urea, N-[3-(4-[2-chloroethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 784210-85-1 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-((4-morpholinylamino)carbonyl)amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl)-4-(1-methylethyl)- (9CI)
 (CA INDEX NAME)




IT 516493-95-1P 516494-06-7P 516494-08-9P
 516494-11-4P 516494-13-6P 516494-14-7P
 516494-16-9P 516494-18-1P 516494-20-5P
 516494-22-7P 516494-24-9P 516494-26-1P
 784210-86-2P 784211-18-3P 784211-19-4P
 784211-20-7P 784211-21-8P 784211-22-9P
 784211-23-0P 784211-24-1P 784211-25-2P
 784211-29-6P 784211-31-0P 784211-32-1P
 784211-33-2P 784211-34-3P 784211-35-4P
 784211-37-6P 784211-38-7P 784211-39-8P
 784211-40-1P 784211-44-5P 784211-45-6P

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)


PAGE 1-A



PAGE 2-A

● 3 HCl

RN 516494-08-9 CAPLUS
 CN Urea, N-[3-[(2-[(cyclopropylmethyl)propylamino]ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 516494-11-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,

SAEED


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

784211-46-7P 784211-47-8P 784211-48-9P
 784211-49-0P 784211-50-3P 784211-51-4P
 784211-52-5P 784211-53-6P 784211-57-0P
 784211-58-1P 784211-59-2P 784211-88-7P
 784211-89-8P 784211-90-1P 784211-91-2P
 784211-92-3P 784211-93-4P 784211-94-5P
 784211-95-6P 784211-96-7P 784211-97-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses); (drug candidate; prepn. of pyrazole derivs. as inhibitors of cyclin-dependent kinases)

RN 516493-95-1 CAPLUS
 CN Urea, N-[3-[(2-[(cyclopropylmethyl)propylamino]ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

NAME)




RN 516494-06-7 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-[(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-c]pyrazol-5-yl)-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)

● 3 HCl

RN 516494-13-6 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[(4-phenoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 516494-14-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[(4-hydroxy-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 1 HCl

RN 516494-16-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(2-methyl-4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A




PAGE 2-A

● 2 HCl

RN 516494-22-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-[(3S)-3-hydroxy-1-pyrrolidinyl]ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 516494-24-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-


SAEED

PAGE 2-A

● 3 HCl

RN 516494-18-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-(2S)-2-(hydroxymethyl)-1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl


RN 516494-20-5 CAPLUS
 CN Urea, N-[3-[(2-[bis(2-hydroxyethyl)amino]ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A

● 3 HCl

RN 516494-20-5 CAPLUS
 CN Urea, N-[3-[(2-[bis(2-hydroxyethyl)amino]ethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


● 3 HCl

RN 516494-26-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784210-86-2 CAPLUS
 CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxylacetyl]-4-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-18-3 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-[2-(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-19-4 CAPLUS
 CN Urea, N-[3-(4-[2-(bis(2-hydroxyethyl)amino)ethoxy]phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-20-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-(4-morpholinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-22-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1-piperidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 784211-21-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(4-morpholinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A

● 3 HCl

RN 784211-23-0 CAPLUS
 CN Urea, N-[3-[4-[2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)ethoxy]-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 4 HCl

RN 784211-24-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-hydroxy-3-(4-morpholinylmethyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 2-A



● 3 HCl

RN 784211-25-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 784211-29-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 784211-31-0 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 784211-32-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● 4 HCl

RN 784211-33-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[2-(4-(1-methylethyl)-1-piperazinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)


PAGE 2-A



PAGE 2-A


● 4 HCl

RN 784211-34-3 CAPLUS
 CN Urea, N-(2,4-dihydro-3-[4-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 784211-35-4 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 784211-37-6 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-[4-(1-methylethyl)-1-piperazinyl]-, dihydrochloride


PAGE 1-A



PAGE 2-A


● 2 HCl

RN 784211-38-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-(2-(1-piperidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-40-1 CAPLUS
 CN 1-Piperazineacetic acid, 4-[[[2,4-dihydro-4-oxo-3-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]amino]-, ethyl ester, trihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl



10820453C>

07/08/2007


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

PAGE 2-A

● 3 HCl

RN 784211-44-5 CAPLUS
 CN Urea, N-[2-(2,4-dihydro-3-[(3-methoxy-4-[(2-(1-pyrrolidinyl)ethoxy]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-45-6 CAPLUS
 CN L-Valine, 2-[4-[(2,4-dihydro-4-oxo-3-[(4-[(2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl]amino)carbonyl]amino]-1-piperazinyl]ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 784211-46-7 CAPLUS
 CN Acetamide, 2-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 784211-47-8 CAPLUS
 CN Urea, N-[2-(2,4-dihydro-3-[(4-((2-methyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 784211-48-9 CAPLUS
 CN Morpholine, 4-[(4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)acetyl]- (9CI) (CA INDEX NAME)



RN 784211-49-0 CAPLUS
 CN 1-Piperazineacetic acid, 4-[(4-[(2,4-dihydro-4-oxo-3-[(4-[(2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl]amino)carbonyl]amino)-1-methylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 2-A

RN 784211-50-3 CAPLUS
 CN 1-Piperazineacetamide, 4-[(4-[(2,4-dihydro-4-oxo-3-[(4-[(2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyra

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-51-4 CAPLUS
CN Pyrrolidine, 1-[4-(2,4-dihydro-5-[[[(4-methyl-1-piperazinyl)amino]carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

● HCl

RN 784211-52-5 CAPLUS
CN Urea,
N-(2,4-dihydro-3-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

● HCl


RN 784211-53-6 CAPLUS
CN Pyrrolidine,
1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]acetyl- (9CI) (CA INDEX NAME)



RN 784211-57-0 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]sulfonyl-, dihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



● 2 HCl


RN 784211-58-1 CAPLUS
CN Piperazine, 1-[(4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]sulfonyl-4-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-59-2 CAPLUS
CN Acetic acid, [4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 784211-88-7 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-{4-[(4-(4-pyridinyl)-1-piperazinyl)methyl]phenyl}indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 784211-89-8 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-{4-[(4-(2-pyrimidinyl)-1-piperazinyl)methyl]phenyl}indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 784211-90-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-{4-[(2-methoxyethyl)-1-piperazinyl)methyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-91-2 CAPLUS
CN Urea, N-[2,4-dihydro-3-{4-[(1-methylethyl)-1-piperazinyl)methyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)


● 2 HCl

RN 784211-92-3 CAPLUS
CN Urea, N-[2,4-dihydro-3-{4-[(2-hydroxy-1-bis(hydroxymethyl)ethylamino)ethyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 784211-93-4 CAPLUS
CN Urea, N-[2,4-dihydro-3-{4-[(2-methylsulfonyl)ethylamino)methyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, monohydrochloride (9CI)


L12 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

RN 784211-94-5 CAPLUS
CN Urea, N-[2,4-dihydro-3-{4-[(2-hydroxy-1-(hydroxymethyl)-1-methylethylamino)methyl]phenyl}-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 784211-95-6 CAPLUS
CN Piperazine, 1-[(4-[(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)acetyl]-4-(2-methoxyethyl)- (CA INDEX NAME)



RN 784211-96-7 CAPLUS
CN Urea,
N-[3-[(4-((4S)-4-amino-3-methyl-3-oxohexyl)amino)methyl]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784211-97-8 CAPLUS
CN Piperazine, 1-[(4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl)phenoxy]acetyl-, monohydrochloride (9CI) (CA INDEX NAME)

DOCUMENT NUMBER: 142:38184
TITLE: Parallel synthesis of acylsemicarbazide libraries: preparation of potent cyclin dependent kinase (cdk) inhibitors
AUTHOR(S): Nugiel, David A.; Vidwans, Anup; Dzierba, Carolyn D.
CORPORATE SOURCE: DuPont Pharmaceuticals, Wilmington, DE, 19880-0336, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(22), 5489-5491
CODEN: BMCLB; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:38184
GI



I




II

AB Potent cyclin dependent kinase inhibitors were prepared using parallel synthesis methodol. Treating advanced intermediate I with a variety of hydrazides [RC(O)NNH2, R = alkyl, aryl, or heteroaryl] in DMSO gave the desired acylsemicarbazides II (R = Pr-i, Bn, Ph, 4-pyridyl, H2NCO, etc.) in good to excellent yield. Several compds. were active against cdk4/D1 and cdk2/E in the low nanomolar range. The SAR indicates a wide variety of substituents are tolerated at the acylsemicarbazide moiety.

IT 360792-89-8


RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(preparation, cyclin dependent kinase inhibition activity and structure-activity relationship of acylsemicarbazide library)

SAEED




● HCl

CN 2-Thiophenecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)





IT 807628-24-6P 807628-25-7P 807628-26-8P
807628-27-9P 807628-28-0P 807628-29-1P
807628-30-4P 807628-31-5P 807628-33-7P
807628-34-8P 807628-35-9P 807628-36-0P
807628-37-1P 807628-38-2P 807628-39-3P
807628-40-6P 807628-41-7P 807628-42-8P
807628-43-9P 807628-44-0P 807628-45-1P
807628-46-2P 807628-47-3P 807628-48-4P
807628-49-5P 807628-50-6P 807628-51-9P
807628-52-0P 807628-53-1P 807628-54-2P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, cyclin dependent kinase inhibition activity and structure-activity relationship of acylsemicarbazide library)
RN 807628-24-6 CAPLUS
CN Propenoic acid, 2-methyl-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 807628-25-7 CAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-,
 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

PAGE 1-A




RN 807628-27-9 CAPLUS
 CN Benzoic acid, 3-nitro-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-28-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-

RN 807628-26-8 CAPLUS
 CN Benzoic acid, 4-methoxy-,
 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)


PAGE 2-A



L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 {[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl}amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-29-1 CAPLUS
 CN Benzoic acid, 3,4,5-trimethoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-30-4 CAPLUS
 CN Benzoic acid, 3-methyl-,
 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 807628-31-5 CAPLUS
 CN Benzoic acid, 3-amino-4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-33-7 CAPLUS
 CN Benzoic acid, 2,5-dichloro-,
 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-


10820453C>

07/08/2007


L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-34-8 CAPLUS
CN Benzoic acid, 3,4-dihydroxy-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-
[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 807628-38-2 CAPLUS
CN 1-Naphthalene carboxylic acid,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-
[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 807628-39-3 CAPLUS
CN Hydrazinecarboxylic acid,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-
(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-y1]amino]carbonyl]-
methyl ester (9CI) (CA INDEX NAME)




RN 807628-40-6 CAPLUS


SAEED

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 807628-35-9 CAPLUS
CN Benzoic acid, 3,5-diamino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-
[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-36-0 CAPLUS
CN 1,2-Hydrazinedicarboxamide,
N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-
(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-y1)-
INDEX NAME




RN 807628-37-1 CAPLUS
CN 1,2-Hydrazinedicarboxamide,
N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-
(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-y1)-N'-phenyl-
(9CI) (CA INDEX NAME)


L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzoic acid, 2-methoxy-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-
(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-41-7 CAPLUS
CN Benzoic acid, 4-methyl-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-
(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-
y1]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 807628-42-8 CAPLUS
CN Benzoic acid, 2-hydroxy-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-43-9 CAPLUS
CN 2-Naphthalene carboxylic acid,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 807628-44-0 CAPLUS
CN Benzoic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-45-1 CAPLUS
CN Benzoic acid, 3,5-dimethoxy-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-46-2 CAPLUS
CN Benzoic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 807628-47-3 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-48-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)


L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 807628-49-5 CAPLUS
CN Benzoic acid, 2,4-dihydroxy-,
2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-50-8 CAPLUS
CN Acetic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-51-9 CAPLUS
CN Benzoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-52-0 CAPLUS
CN Acetic acid, aminoxo-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 807628-53-1 CAPLUS
CN Benzoic acid, 3-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 807628-54-2 CAPLUS
CN Benzoic acid, 4-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-[(2-(trimethylsilyl)ethoxy)methyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




IT 360792-67-2P 360792-68-3P 360792-69-4P
360792-70-7P 360792-71-8P 360792-72-9P
360792-73-0P 360792-76-3P 360792-77-4P
360792-78-5P 360792-79-6P 360792-80-9P
360792-81-0P 360792-83-2P 360792-84-3P
360792-85-4P 360792-86-5P 360792-87-6P
360792-88-7P 360792-90-1P 360792-91-2P
489448-91-1P 489448-92-2P 489448-93-3P
807628-55-3P 807628-56-4P 807628-57-5P
807628-58-6P 807628-60-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(preparation, cyclin dependent kinase inhibition activity and structure-activity relationship of acylsemicarbazide library)

RN 360792-67-2 CAPLUS
CN Benzoic acid, 3,5-dimethoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-68-3 CAPLUS
CN 4-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-69-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-70-7 CAPLUS
 CN Benzoic acid, 3,4-dihydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-71-8 CAPLUS
 CN Benzoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-72-9 CAPLUS
 CN Benzoic acid, 3-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-73-0 CAPLUS
 CN Benzoic acid, 4-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-76-3 CAPLUS
 CN Benzoic acid, 2-methoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (9CI) (CA INDEX NAME)




RN 360792-77-4 CAPLUS
 CN Benzoic acid, 2-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-78-5 CAPLUS
 CN Benzoic acid, 3,5-diamino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-79-6 CAPLUS
 1-Naphthalene carboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (9CI) (CA INDEX NAME)


L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-80-9 CAPLUS
 CN 1,2-Hydrazinedicarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 360792-81-0 CAPLUS
 CN 1,2-Hydrazinedicarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 360792-83-2 CAPLUS

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzoic acid, 4-methyl-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (9CI) (CA INDEX NAME)


RN 360792-84-3 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-85-4 CAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 360792-86-5 CAPLUS
 CN Benzoic acid, 4-methoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)


L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-87-6 CAPLUS
 CN Benzoic acid, 3-nitro-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-88-7 CAPLUS
 CN Benzoic acid, 3,4,5-trimethoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-90-1 CAPLUS
CN Benzoic acid, 3-methyl-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-91-2 CAPLUS
CN Benzoic acid, 2,5-dichloro-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 807628-55-3 CAPLUS
CN Propanoic acid, 2-methyl-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)





RN 807628-56-4 CAPLUS
CN Benzoic acid, 3-amino-4-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 489448-91-1 CAPLUS
CN Benzoic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)



RN 489448-92-2 CAPLUS
CN Benzeneacetic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 807628-57-5 CAPLUS
CN Benzoic acid, 2,4-dihydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 807628-58-6 CAPLUS
CN Acetic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 807628-60-0 CAPLUS
CN Acetic acid, 2-amino-2-oxo-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203550 CAPLUS
DOCUMENT NUMBER: 140:253559
TITLE: Preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents
INVENTOR(S): Nugiel, David; Carini, David; DiMeo, Susan; Vidwans, Anup; Yue, Eddy
PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 906,963.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004048844	A1	20040311	US 2003-427540	20030501
US 6291504	B1	20010918	US 2000-692023	20001019
US 2003073686	A1	20030417	US 2001-906963	20010716
US 6593356	B2	20030715		
US 2005261353	A1	20051124	US 2005-64758	20050224
			US 1999-160713P	P 19991020
			US 2000-692023	A2 20001019
			US 2001-906963	A2 20010716
			US 2003-427540	B1 20030501

PRIORITY APPLN. INFO.:

GI

OTHER SOURCE(S): MARPAT 140:253559


GI



AB The title compds. [I; X = O, S, NR (wherein R = H, alkyl, (un)substituted NH₂); R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.] that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclins A-G and therefore are useful in treating cancer or other proliferative diseases (no data), were prepared. E.g., a 3-step synthesis of indeno[1,2-c]pyrazol-4-one II, starting with di-Me 3-nitrophthalate, was

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 247149-85-5P, 3-[4-(4-tert-Butoxycarbonyl-1-piperazinyl)phenyl]-5-[[[(4-morpholinyl)amino]carbonyl]amino]indeno[1,2-c]pyrazol-4-one trifluoroacetate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of indenopyrazolones as anti-cancer and anti-proliferative agents)
RN 247149-85-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2,4-dihydro-5-[(4-morpholinyl)amino]carbonyl)amino]-4-oxindeno[1,2-c]pyrazol-3-yl]phenyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 669764-28-7 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
CRN 247149-86-6
CMF C25 H27 N7 O3

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




IT 247148-81-8P, 3-(4-Methoxyphenyl)-5-[(phenylcarbamoyl)amino]indeno[1,2-c]pyrazol-4-one 247148-82-9P, 3-(4-Methoxyphenyl)-5-[(propylcarbamoyl)amino]indeno[1,2-c]pyrazol-4-one 247148-83-0P, 3-(4-Methoxyphenyl)-5-[(4-aminobenzylcarbamoyl)amino]indeno[1,2-c]pyrazol-4-one 247148-84-1P, 3-(4-Methoxyphenyl)-5-[(4-pyridylmethyl)carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-02-6P, 3-(4-Methoxyphenyl)-5-(carbamoylamino)indeno[1,2-c]pyrazol-4-one 247149-04-8P, 3-(4-Methoxyphenyl)-5-[(dimethylamino)carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-05-9P, 3-(4-Methoxyphenyl)-5-[(morpholinino)carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-06-0P, 3-(4-Methoxyphenyl)-5-[(cyclohexylaminocyclohexyl)carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-07-1P, 3-(4-Methoxyphenyl)-5-[(4-methylpiperazin-1-yl)carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-08-7P, 3-(4-(1-Piperazinyl)phenyl)-5-[(hydrazinocarbonyl)amino]indeno[1,2-c]pyrazol-4-one 247149-93-5P, 3-(4-(4-Ethyl-1-piperazinyl)phenyl)-5-[(4-morpholinyl)amino]carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-94-6P, 3-(4-(4-isopropyl-1-piperazinyl)phenyl)-5-[(4-morpholinyl)amino]carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247150-00-5P, 3-(4-(Dimethylamino)phenyl)-5-[(4-methyl-

3-(4-(1-Piperazinyl)phenyl)-5-[(aminocarbonyl)amino]indeno[1,2-c]pyrazol-4-one 247149-88-8P, 3-(4-(1-Piperazinyl)phenyl)-5-[(hydrazinocarbonyl)amino]indeno[1,2-c]pyrazol-4-one 247149-93-5P, 3-(4-(4-Ethyl-1-piperazinyl)phenyl)-5-[(4-morpholinyl)amino]carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247149-94-6P, 3-(4-(4-isopropyl-1-piperazinyl)phenyl)-5-[(4-morpholinyl)amino]carbamoyl]amino]indeno[1,2-c]pyrazol-4-one 247150-00-5P, 3-(4-(Dimethylamino)phenyl)-5-[(4-methyl-

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


360792-68-3P, 3-[(4-Methoxyphenyl)-5-[[[2-(isocitonoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-69-4P, 3-[(4-Methoxyphenyl)-5-[[[2-(nicotinoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-70-7P, 3-[(4-Methoxyphenyl)-5-[[[2-(3,4-dihydroxybenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-71-8P, 3-[(4-Methoxyphenyl)-5-[[[2-(4-hydroxybenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-72-9P, 3-[(4-Methoxyphenyl)-5-[[[2-(3-aminobenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-73-0P, 3-[(4-Methoxyphenyl)-5-[[[2-(4-aminobenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-74-1P, 3-[(4-Methoxyphenyl)-5-[[[2-(2-aminobenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-75-2P, 3-[(4-Methoxyphenyl)-5-[[[2-(4-N,N-dimethylamino)benzoyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 360792-77-4P, 3-[(4-Methoxyphenyl)-5-[[[2-(2-hydroxybenzoyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 489448-91-1P, 3-[(4-Methoxyphenyl)-5-[[[2-(benzoylhydrazinyl)amino]indeno[1,2-c]pyrazol-4-one
 489448-92-2P, 3-[(4-Methoxyphenyl)-5-[[[2-(2-phenylacetyl)hydrazinyl]carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 489448-93-3P, 3-[(4-Methoxyphenyl)-5-[[[2-(2-methoxyacarbonylhydrazinyl)carbonyl]amino]indeno[1,2-c]pyrazol-4-one
 669764-30-1P, 3-[(4-Methyl-1-piperazinyl)phenyl]-5-[[[4-(morpholinyl)amino]carbonyl]amino]indeno[1,2-c]pyrazol-4-one trifluoroacetate
 RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (drug candidate; prepn. of indenopyrazolones as anti-cancer and anti-proliferative agents)

RN 247148-81-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)




RN 247148-82-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-propyl- (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247148-83-0 CAPLUS
 CN Urea, N-[(4-aminophenyl)methyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (CA INDEX NAME)




RN 247148-84-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-pyridinylmethyl)- (CA INDEX NAME)


L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-02-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N,N'-diphenylindeno[1,2-c]pyrazol-4-one (CA INDEX NAME)




RN 247149-03-7 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)




RN 247149-04-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-methyl- (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-05-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 247149-06-0 CAPLUS
 CN Urea, N-[(1R,2S)-2-aminocyclohexyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 247149-07-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-87-7 CAPLUS

CN Urea, [2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 247149-88-0 CAPLUS

CN Hydrazinecarboxamide, N-(2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 247149-93-5 CAPLUS

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-68-3 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-69-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Urea, N-[3-(4-ethyl-1-piperazinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

RN 247149-94-6 CAPLUS


CN Urea, N-[2,4-dihydro-3-(4-(4-(1-methylethyl)-1-piperazinyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 247150-88-5 CAPLUS


CN Urea, N-[3-(dimethylaminophenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-methyl-1-piperazinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-70-7 CAPLUS

CN Benzoic acid, 3,4-dihydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-71-8 CAPLUS


CN Benzoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 360792-72-9 CAPLUS
 CN Benzoic acid, 3-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-73-0 CAPLUS
 CN Benzoic acid, 4-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-74-1 CAPLUS
 CN Benzoic acid, 2-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-75-2 CAPLUS
 CN Benzoic acid, 4-(dimethylamino)-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-77-4 CAPLUS
 CN Benzoic acid, 2-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 489448-91-1 CAPLUS
 CN Benzoic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)


L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 489448-92-2 CAPLUS
 CN Benzenesacetic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)



RN 489448-93-3 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 669764-30-1 CAPLUS
 CN Urea,
 N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl-trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 247149-92-4
 CMF C26 H29 N7 O3

L12 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

CM 2
CRN 76-05-1
CMF C2 H F3 O2


L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 454221-46-6 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[{4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl}amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,16-dioxo-, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:182368 CAPLUS

DOCUMENT NUMBER: 140:229401

TITLE: Three hybrid assay system for isolating

ligand-binding

INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph

PATENT ASSIGNEE(S): Gpc Biotech Inc., USA; Gpc Biotech AG

SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 7135550	B2	20061114		
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:				
			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-U56677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223


AB The invention provides compds. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g. a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

IT 454221-46-6P 454221-47-7P 454221-48-8P
 RL BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-C




RN 454221-47-7 CAPLUS


CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 25-[(4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,22-dioxo-, (25S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 454221-48-8 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[{4-[(2,4-diamino-6-pteridinyl)methyl]methylamino}benzoyl]amino]-1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-2,16-dioxo-, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 452913-27-8D, conjugates
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
 RN 452913-27-8 CAPLUS
 CN Acetic acid, [4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-

PAGE 1-B



IT 452913-28-9P 452913-29-0P 452913-30-3P
 452913-31-4P 452913-35-8P 452913-36-9P
 452913-37-0P 452913-38-1P 452913-39-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)


RN 452913-28-9 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-ylphenoxy]-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 452913-29-0 CAPLUS
 CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 1-[(4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-ylphenoxy)-25-[(4-(methylamino)benzoyl)amino]-2,22-dioxo-, 1,1-dimethylethyl ester, (25S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10820453C>

07/08/2007

L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN



(Continued)
PAGE 1-C




RN 452913-30-3 CAPLUS
CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[{[4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl}amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-B




RN 452913-31-4 CAPLUS
CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid, 25-[{[4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl}amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,22-dioxo-, 1,1-dimethylethyl ester, (25S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-C


L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A





L12 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 452913-35-8 CAPLUS
CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 452913-36-9 CAPLUS
CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-C




RN 452913-37-0 CAPLUS
CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 452913-38-1 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid,
 1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester,
 (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



t-BuO


PAGE 1-B



RN 452913-39-2 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[(4-[(2,4-diamino-6-pteridinyl)methyl]methylamino)benzoyl]amino]-1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:319902 CAPLUS
 DOCUMENT NUMBER: 138:338168
 TITLE: Preparation arylalkyl substituted pyrazolo[5,4-d]pyrimidines and related analogs as inhibitors of cyclin-dependent kinases
 INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur F.; Ram, Siya; Wang, Zhonghuo; Oalmann, Chris; Murchi, Krishna K.
 PATENT ASSIGNEE(S): GPC Biotech Inc., USA
 SOURCE: PCT Int. Appl., 79 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033499	A2	20030424	WO 2002-U33052	20021015
WO 2003033499	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463571	A1	20030424	CA 2002-2463571	20021015
AU 2002361570	A1	20030428	AU 2002-361570	20021015
EP 1446405	A2	20040818	EP 2002-797047	20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, KK				
JP 2005511535	T	20050428	JP 2003-536238	20021015
US 2005090471	A1	20050428	US 2003-492116	20021015
US 2003162797	A1	20030828	US 2002-321284	20021217
US 6753329	B2	20040622		
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:			US 2001-329437P	P 20011015
			US 2001-336962P	P 20011203
			US 2001-272932P	P 20010302
			US 2002-91177	A2 20020304
			WO 2002-U56677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-U33052	W 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

OTHER SOURCE(S): MARPAT 138:338168
 GI

MARPAT 138:338168

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [$W = O$, NR'; X = halo, F, Cl, Br, I; Y = H, X; R1 = H, PO(R')2, MnO; R2 = H, MnO, provided that one and only one of R1/R2 = H; M = CH_2 , O, 900-2, etc.; n = 1-5; Q = tertiary amino] are prepared. For instance, (1-chloro-2-methylpropylidene)methane-1,1-dicarbonitrile (preparation given) is reacted with 2,6-dichlorophenylhydrazine-HCl (THF, Et3N, reflux, 18 h) to give 5-amino-1-(2,6-dichlorophenyl)-3-isopropyl-1H-pyrazole-4-carbonitrile. This intermediate is converted to the corresponding amide (H2SO4) and reacted with Et 4-hydroxyphenylacetate (EtOH, NaOtB) resulting in the formation of the corresponding pyrazolo[3,4-d]pyrimidin-4-one intermediate. This was derivatized with di-(tert-butyl) N,N-diisopropylphosphoramide (DMF, tetrazole, 3 h), the resulting intermediate treated with MCPBA and finally deprotected (TFA) to give II. Compds. of the invention were tested for activity against cyclin dependent kinases, e.g., Cdk2/cyclin E, Cdk4/cyclin D1, etc. I are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. are useful for treating subjects having disorders associated with excessive cell proliferation.

IT 516493-95-1P 516494-04-5P 516494-05-6P


L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

516494-06-7P 516494-07-8P 516494-08-9P
516494-09-0P 516494-10-3P 516494-11-4P
516494-12-5P 516494-13-6P 516494-14-7P
516494-15-8P 516494-16-9P 516494-17-0P
516494-18-1P 516494-19-2P 516494-20-5P
516494-21-6P 516494-22-7P 516494-23-8P
516494-24-9P 516494-25-0P 516494-26-1P
516494-27-2P

RL: PAC (Pharmacological activity); **SPN** (Synthetic preparation); **THU** (Therapeutic use); **BIOL** (Biological study); **PREP** (Preparation); **USES** (Uses)
(prepn. arylalkyl substituted pyrazolo[5,4-d]pyrimidines and indeno[1,2-c]pyrazoles as inhibitors of cyclin-dependent kinases)


RN 516493-95-1 CAPLUS
CN Urea, N-[3-[4-[2-[(cyclopropylmethyl)propylamino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

INDEX
(NAME)




RN 516494-04-5 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[2-[(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● 2 HCl


RN 516494-05-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[2-[(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 516494-06-7 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)


L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




● 3 HCl

RN 516494-07-B CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 516494-08-9 CAPLUS
CN Urea, N-[3-[4-[2-[(cyclopropylmethyl)propylamino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●3 HCl


RN 516494-09-0 CAPLUS
 CN Urea, N-[3-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 516494-10-3 CAPLUS
 CN Urea, N-[3-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 516494-11-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-(4-[2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 516494-12-5 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-(4-[2-(1-pyrrolidinyl)ethoxy]phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 516494-13-6 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-(4-(phosphonoxy)phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 516494-14-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●4 HCl


RN 516494-15-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-hydroxy-3-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 516494-16-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[2-methyl-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A

● 3 HCl

RN 516494-17-0 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(2-methyl-4-[2-(1-pyrrolidinyl)ethoxyphenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 516494-21-6 CAPLUS
 CN Urea, N-[3-[4-[2-(bis(2-hydroxyethyl)amino)ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 516494-22-7 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-(4-[2-((3S)-3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl)-

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 516494-18-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-((2S)-2-(hydroxymethyl)-1-

pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 516494-19-2 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(2-((2S)-2-(hydroxymethyl)-1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 516494-20-5 CAPLUS
 CN Urea, N-[3-[4-[2-(bis(2-hydroxyethyl)amino)ethoxy]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)-,

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 516494-23-8 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-(2-((3S)-3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 516494-24-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-methyl-4-(2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- trihydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

● 3 HCl


RN 516494-25-0 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[3-methyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 516494-26-1 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 516494-27-2 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 516493-91-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation arylalkyl substituted pyrazolo[5,4-d]pyrimidines and
 indeno[1,2-c]pyrazoles as inhibitors of cyclin-dependent kinases)
 RN 516493-91-7 CAPLUS
 CN Urea, N-[3-[4-(2-chloroethoxy)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:300613 CAPLUS
 DOCUMENT NUMBER: 138:304281
 TITLE: Preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as cyclin dependent kinase inhibitors for treating cancer and other proliferative diseases
 INVENTOR(S): Nugiel, David; Carini, David; Dimeo, Susan; Vidwans, Anup; Yue, Eddy
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. 6,291,504.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073686	A1	20030417	US 2001-906963	20010716
US 6593356	B2	20030715		
US 6291504	B1	20010918	US 2000-692023	20000109
CA 2453594	A1	20030130	CA 2002-2453594	20020716
WO 2003007883	A2	20030130	WO 2002-US22663	20020716
WO 2003007883	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, 2M, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002318254	A1	20030303	AU 2002-318254	20020716
EP 1417177	A2	20040512	EP 2002-748186	20020716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011203	A	20040928	BR 2002-11203	20020716
CN 1553900	A	20041208	CN 2002-817761	20020716
JP 2004536853	T	20041209	JP 2003-513492	20020716
HU 200401588	A2	20050128	HU 2004-1588	20020716
US 2004048844	A1	20040311	US 2003-427540	20030501
NO 2004000175	A	20040312	NO 2004-175	20040115
ZA 2004000332	A	20050415	ZA 2004-332	20040115
IN 2004DN00119	A	20050401	IN 2004-DN119	20040116
US 2005261353	A1	20051124	US 2005-64758	20050224
PRIORITY APPLN. INFO.:			US 1999-160713P	P 19991020
			US 2000-692023	A2 20000109
			US 2001-906963	A 20010716
			WO 2002-US22663	W 20020716
			US 2003-427540	B1 20030501

OTHER SOURCE(S): MARPAT 138:304281
 GI


L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. [I; X = O, S, NR (wherein R = H, alkyl, (un)substituted NH₂); R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.] that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G and therefore are useful in treating cancer or other proliferative diseases (no data), were prepared. E.g., a 3-step synthesis of indeno[1,2-c]pyrazol-4-one II, starting with di-Me 3-nitrophthalate, was given.

IT 247149-85-5P 247149-86-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)

RN 247149-85-S CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 247149-86-6 CAPLUS
CN Urea,
N-(2,4-dihydro-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




IT 247149-81-8P 247149-82-9P 247149-83-0P
247149-84-1P 247149-02-6P 247149-03-7P
247149-04-8P 247149-05-9P 247149-06-0P
247149-07-1P 247149-87-7P 247149-88-8P
247149-90-2P 247149-91-3P 247149-92-4P
247149-93-5P 247149-94-6P 247150-88-5P
360792-68-3P 360792-69-4P 360792-70-7P
360792-71-8P 360792-72-9P 360792-73-0P
360792-74-1P 360792-75-2P 360792-77-4P
485820-04-0P 489446-91-1P 489446-92-2P
489446-93-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)

RN 247149-81-8 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-phenyl- (CA INDEX NAME)


L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-82-9 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-propyl- (9CI) (CA INDEX NAME)




RN 247149-83-0 CAPLUS
CN Urea, N-[(4-aminophenyl)methyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 247149-84-1 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-pyridinylmethyl)- (CA INDEX NAME)


L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-02-6 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (CA INDEX NAME)




RN 247149-03-7 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)




RN 247149-04-8 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-methyl- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-05-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 247149-06-0 CAPLUS
 CN Urea,
 N-[(1R,2S)-2-aminocyclohexyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-90-2 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 247149-91-3 CAPLUS
 CN Urea, N-[(4-aminomethyl)-1-piperidinyl]-N'-(2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)


L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 247149-07-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

RN 247149-87-7 CAPLUS
 CN Urea,
 [2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 247149-88-8 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-92-4 CAPLUS
 CN Urea,
 N-[2,4-dihydro-3-(4-(4-methyl-1-piperazinyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247149-93-5 CAPLUS
 CN Urea, N-[3-(4-(4-ethyl-1-piperazinyl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-94-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-[4-(1-methylethyl)-1-piperazinyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247150-68-5 CAPLUS
 CN Urea, N-[3-[4-(dimethylamino)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-68-3 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-69-4 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-70-7 CAPLUS
 CN Benzoic acid, 3,4-dihydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-71-8 CAPLUS
 CN Benzoic acid, 4-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)


L12 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-72-9 CAPLUS
 CN Benzoic acid, 3-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-73-0 CAPLUS
 CN Benzoic acid, 4-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-74-1 CAPLUS
CN Benzoic acid, 2-amino-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-75-2 CAPLUS
CN Benzoic acid, 4-(dimethylamino)-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl (9CI) (CA INDEX NAME)




RN 360792-77-4 CAPLUS
CN Benzoic acid, 2-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl (CA INDEX NAME)




RN 485820-04-0 CAPLUS
CN Urea, N-(2-aminocyclohexyl)-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 489448-91-1 CAPLUS
CN Benzoic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl (CA INDEX NAME)



RN 489448-92-2 CAPLUS
CN Benzenesacitic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl (CA INDEX NAME)



RN 489448-93-3 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]-, methyl ester (CA INDEX NAME)



L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:76552 CAPLUS

DOCUMENT NUMBER: 138:122642

TITLE: Preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents

INVENTOR(S): Nuigiel, David; Carini, David; Dimeo, Susan; Vidwans, Anup; Yue, Eddy

PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXRD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200307983	A2	20030130	WO 2002-US22663	20020716
WO 200307983	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GN, KE, LS, MW, RZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GG, GW, ML, MR, NE, SN, TD, TG				
US 2003073686	A1	20030417	US 2001-906963	20010716
US 6593356	B2	20030715		
CA 2453594	A1	20030130	CA 2002-2453594	20020716
AU 2002318254	A1	20030303	AU 2002-318254	20020716
EP 1417177	A2	20040512	EP 2002-748186	20020716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011203	A	20040928	BR 2002-11203	20020716
JP 2004536853	T	20041209	JP 2003-513492	20020716
HU 200401588	A2	20050128	HU 2004-1588	20020716
NO 2004000175	A	20040312	NO 2004-175	20040115
IN 2004DN00119	A	20050401	IN 2004-DN119	20040116
PRIORITY APPLN. INFO.:			US 2001-906963	A 20010716
			US 1999-160713P	P 19991020
			US 2000-692023	A2 20001019
			WO 2002-US22663	W 20020716

OTHER SOURCE(S): MARPAT 138:122642
GI


L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB: The title compds. [I; X = O, S, NR (wherein R = H, alkyl, (un)substituted (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.) that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G and therefore are useful in treating cancer or other proliferative diseases (no data). Were prepared. E.g., a 3-step synthesis of indeno[1,2-c]pyrazol-4-one II, starting with di-Me 3-nitrophthalate, was given.

IT: 247149-85-5 247149-86-6
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)


RN: 247149-85-5 CAPLUS
CN: 1-Piperazinecarboxylic acid, 4-[{[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxindeno[1,2-c]pyrazol-3-yl}phenyl]-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)



RN: 247149-86-6 CAPLUS

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN: Urea, N-[2,4-dihydro-3-{4-(1-piperazinyl)phenyl}indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




IT: 247148-81-8P 247148-82-9P 247148-83-0P
247148-84-1P 247149-02-6P 247149-03-7P
247149-04-8P 247149-05-9P 247149-06-0P
247149-07-1P 247149-87-7P 247149-88-8P
247149-90-2P 247149-91-3P 247149-92-4P
247149-93-5P 247149-94-6P 247150-88-5P
360792-68-3P 360792-69-4P 360792-70-7P
360792-71-8P 360792-72-9P 360792-73-0P
360792-74-1P 360792-75-2P 360792-77-4P
489448-04-0P 489448-91-1P 489448-92-2P
489448-93-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 5-substituted indeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)


RN: 247148-81-8 CAPLUS

CN: Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)




RN: 247148-82-9 CAPLUS
CN: Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-propyl- (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN: 247148-83-0 CAPLUS
CN: Urea, N-[4-(aminomethyl)methyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN: 247148-84-1 CAPLUS
CN: Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-pyridinylmethyl)- (CA INDEX NAME)


10820453C>

07/08/2007


L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-02-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (CA INDEX NAME)




RN 247149-03-7 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)



RN 247149-04-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
N'-methyl- (9CI) (CA INDEX NAME)


RN 247149-05-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 247149-06-0 CAPLUS
 CN Urea,
 N-[(1R,2S)-2-aminocyclohexyl]-N'-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-07-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 247149-87-7 CAPLUS
 CN Urea,
 (2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-90-2 CAPLUS
 CN Urea,
 N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 247149-91-3 CAPLUS
 CN Urea, N-[(4-(aminomethyl)-1-piperidinyl)-N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 247149-88-8 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)


SAEED

Page 84

10820453C>


07/08/2007

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-92-4 CAPLUS


CN Urea, N-[2,4-dihydro-3-(4-(4-methyl-1-piperazinyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 247149-93-5 CAPLUS


CN Urea, N-[3-(4-(4-ethyl-1-piperazinyl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-68-3 CAPLUS


CN 4-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)



RN 360792-69-4 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-94-6 CAPLUS

CN Urea, N-[2,4-dihydro-3-[4-(4-(1-methylethyl)-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247150-88-5 CAPLUS

CN Urea, N-[3-(4-(dimethylamino)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-methyl-1-piperazinyl- (9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-70-7 CAPLUS


CN Benzoic acid, 3,4-dihydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-71-8 CAPLUS

CN Benzoic acid, 4-hydroxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-72-9 CAPLUS
CN Benzoic acid, 3-amino-, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (CA INDEX NAME)




RN 360792-73-0 CAPLUS
CN Benzoic acid, 4-amino-, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-74-1 CAPLUS
CN Benzoic acid, 2-amino-, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-75-2 CAPLUS
CN Benzoic acid, 4-(dimethylamino)-, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-77-4 CAPLUS
CN Benzoic acid, 2-hydroxy-, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (CA INDEX NAME)




RN 485820-04-0 CAPLUS
CN Urea, N-(2-aminocyclohexyl)-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-(9CI) (CA INDEX NAME)


L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 489448-91-1 CAPLUS
CN Benzoic acid, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (CA INDEX NAME)



RN 489448-92-2 CAPLUS
CN Benzenesacetic acid, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]hydrazide (CA INDEX NAME)




RN 489448-93-3 CAPLUS
CN Hydrazinecarboxylic acid, 2-[{[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino}carbonyl]-, methyl ester (CA INDEX NAME)

L12 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L12 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2007 ACS on STM
ACCESSION NUMBER: 2003:42668 CAPLUS
DOCUMENT NUMBER: 138:106693
TITLE: Preparation of acylaminoindenopyrazolones as cyclin-dependent kinase inhibitors.
INVENTOR(S): Carini, David J.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004491	A1	20030116	WO 2002-0521449	20020708
W:	AG, AL, AM, AT, AU, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EZ, EC, EE, ES, FI, GL, GB, GD, GE, GH, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MK, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, US, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MM, MZ, SD, SL, SI, FR, GB, GR, IE, IT, LU, MC, NL, CH, CY, CZ, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, NE, SN, TD, TG			
CA 2453104	A1	20030116	CA 2002-2453104	20020708
AU 2002354807	A1	20030121	AU 2002-354807	20020708
EP 1404670	A1	20040407	EP 2002-752192	20020708
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 2004242869	A1	20041202	US 2004-482494	20040701
PRIORITY APPLN. INFO.:			US 2001-303519P	P 20010706
			WO 2002-1851449	20020708


OTHER SOURCE(S): MARPAT 138:106693
GI




L12 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 AB Title compds.: [I; R₁ = H, alkyl; R₂ = alkoxy, NR3R4, CH2NR3R4]; R₃ = H, morpholinyl; R₄ = H, aminocyclohexyl; R3R4 = atoms to form a (substituted) 6-membered heterocycle, which were prepared as cyclin dependent kinase inhibitors (no date). Thus, Ph [(2-(4-methoxybenzoyl)-1,3-dioxindan-4-yl)carbamate (preparation given) was heated with 4-aminomorpholine and 4-dimethylaminopyridine in Me₂SO at 80° for 3 h to give 100% tricarbonyl urea derivative, which was refluxed 3 h with NH₄ and p-toluenesulfonic acid in EtOH to give 1-(3-(4-methoxyphenyl)-4-oxo-2,4-dihydro-1H-quinolin-2-yl)-2-(cyclopropylmethyl)-3-morpholin-4-ylurea.

IT dihydroindeno[1,2-c]pyrazolo-5-y]l)-J-morpholin-4-ylurea.
247149-02-6P 247149-05-9P 485820-04-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of a
inhibitors)
RN 247149-02-6 CAPLUS
CN Urea-N-[2,4-dihydro-




RN 247149-05-9 CAPLUS
CN Urea, N-[2-(4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl] (CA INDEX NAME)



RN 485820-04-0 CAPLUS
CN Urea, N-(2-aminocyclohexyl)-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:808527 CAPLUS
 DOCUMENT NUMBER: 138:19122
 TITLE: Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern
 AUTHOR(S): Nugiel, David A.; Vidwans, Anup; Etzkorn, Anna-Marie; Rossi, Karen A.; Benfield, Pamela A.; Burton, Catherine R.; Cox, Sarah; Doleniak, Deborah; Seitz, Steven P.
 CORPORATE SOURCE: Bristol-Myers Squibb Company, Wilmington, DE, 19880-0336, USA
 SOURCE: Journal of Medicinal Chemistry (2002), 45(24), 5224-5232
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:19122
 AB We disclose a novel series of indenopyrazole-based cyclin-dependent kinase (CDK) inhibitors. Kinetic expts. confirmed our initial mol. modeling studies that the compds. are competitive with respect to ATP (ATP) and bind in the kinase ATP pocket. A unique combination of active pharmacophores led us to a series of semicarbazide-based inhibitors that are highly potent against CDK2 and CDK4 while maintaining selectivity against other relevant serine/threonine kinases. These compds. were active against a transformed human colon cancer cell line (HTCL16) while maintaining an acceptable margin of activity against a normal fibroblast cell line. The compds. were found to be highly protein bound in our cell-based assay with the exception of one compound, which maintained a reasonable level of activity in the presence of human plasma proteins.

IT 247149-81-0P 247149-84-1P 364733-05-7P
 478162-11-7P 478162-12-0P 478162-13-9P
 478162-14-0P 478162-15-1P
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and evaluation of indenopyrazoles as CDK inhibitors)


RN 247149-81-0 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)

RN 247149-84-1 CAPLUS

L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 364733-85-7 CAPLUS
 CN Urea, N-butyl-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (CA INDEX NAME)



RN 478162-11-7 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)


L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 478162-12-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(phenylmethyl)- (CA INDEX NAME)


RN 478162-13-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 478162-14-0 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methoxyphenyl)methyl- (9CI) (CA INDEX NAME)


L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478162-15-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 247149-02-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis and evaluation of indenopyrazoles as CDK inhibitors)
 RN 247149-02-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (CA INDEX NAME)



L12 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:696096 CAPLUS
DOCUMENT NUMBER: 137:197882
TITLE: Three hybrid assay system
INVENTOR(S): Becker, Frank; Come, John H.; Kley, Nikolai
PATENT ASSIGNEE(S): Gpc Biotech Ag, Germany; Gpc Biotech Inc.
SOURCE: PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070662	A2	20020912	WO 2002-U96677	20020304
WO 2002070662	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2439263	A1	20020912	CA 2002-2439263	20020304
AU 2002254117	A1	20020919	AU 2002-254117	20020304
EP 1364212	A2	20031126	EP 2002-723332	20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005516580	T	20050609	JP 2002-570690	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPN. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2001-336962P	P 20011203
			US 2002-91177	A2 20020304
			WO 2002-U96677	W 20020304
			US 2002-234985	A2 20020903
			WO 2002-U533052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

AB The invention concerns compns. and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of

L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hybrid ligand compds. In general the invention provides a three hybrid assay system and reagents for the identification of the protein binding partner of a selected small pharmaceutical agent. Likewise, the

invention also provides methods and reagents for the identification of a small pharmaceutical agent binding partner of a selected protein. Once detected, the invention further provides methods for monitoring the interaction of the pharmaceutical agent and its protein binding partner that can be used to detect competitors of the interaction.

IT 452913-30-3P 452913-31-4P 454221-46-6P, GPC
286004 454221-47-7P, GPC 286026 454221-48-8P, GPC
285993

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(three hybrid assay system)


RN 452913-30-3 CAPLUS
CN 6,9,12-Trioxa-3,15-diazasicosan-20-oic acid, 19-[[4-[(2,4-diamino-6-pteridinylmethyl)methylamino]benzoyl]amino]-1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A

L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




PAGE 1-C




RN 452913-31-4 CAPLUS
CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
25-[[4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]amino]-1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxindeno[1,2-c]pyrazol-3-yl]phenoxy]-2,22-dioxo-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



IT 452913-27-0P 452913-28-9P 452913-29-0P
 452913-35-0P 452913-36-9P 452913-37-0P
 452913-38-1P 452913-39-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (three hybrid assay system)
 RN 452913-27-8 CAPLUS


L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Acetic acid, [4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)- (9CI) (CA INDEX NAME)



RN 452913-28-9 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 452913-29-0 CAPLUS
 CN 6,9,12,15,18-Pentaoxa-3,21-diazahexacosan-26-oic acid,
 1-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenoxy)-25-[(4-(methylamino)benzoyl)amino]-2,22-dioxo-,
 1,1-dimethylethyl ester, (25S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-C



RN 452913-35-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-hydroxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 452913-36-9 CAPLUS
 CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 452913-37-0 CAPLUS


L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Indeno[1,2-c]pyrazole-2(4H)-acetic acid, 3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino)-4-oxo- (9CI) (CA INDEX NAME)




RN 452913-38-1 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid,
 1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-19-[(4-(methylamino)benzoyl)amino]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B



RN 452913-39-2 CAPLUS
 CN 6,9,12-Trioxa-3,15-diazaeicosan-20-oic acid, 19-[(4-[(2,4-diamino-6-pteridinyl)methyl]methylamino)benzoyl]amino]-1-[3-(4-hydroxyphenyl)-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-2(4H)-yl]-2,16-dioxo-, 1,1-dimethylethyl ester, (19S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L12 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002-449673 CAPLUS

DOCUMENT NUMBER: 137:20389

TITLE: Preparation of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors.

INVENTOR(S): Carini, David J.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046182	A1	20020613	WO 2001-US46904	20011207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2430376	A1	20020613	CA 2001-2430376	20011207
AU 200228849	A	20020618	AU 2002-28849	20011207
US 2002091127	A1	20020711	US 2001-10979	20011207
US 6849631	B2	20050201		
EP 1351956	A1	20031015	EP 2001-989969	20011207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR				
JP 2004538247	T	20041224	JP 2002-547920	20011207
PRIORITY APPLN. INFO.: US 2000-254116P			US 2000-254116P	P 20001208
			WO 2001-US46904	W 20011207

OTHER SOURCE(S): MARPAT 137:20389
 GI




AB Title compds. [I; X = O, S; R1 = (substituted) carbocyclyl, heterocyclyl; R2 = H, (substituted) alkyl, alkenyl alkynyl, carbocyclyl, heterocyclyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl]; with provisos, were prepared as cdk inhibitors (no data). Thus, 3-(4-piperazinophenyl)-5-[(N-methyl-N-(2-pyridinyl)amino)carbamoylamino]indenopyrazolone was prepared in several steps starting from 4-piperazinacetophenone.

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 435337-10-3P 435337-11-4P 435337-13-6P
 435337-14-7P 435337-16-9P 435337-18-1P
 435337-20-5P 435337-22-7P 435337-24-9P
 435337-26-1P 435337-28-3P 435337-30-7P
 435337-32-9P 435337-34-1P 435337-36-3P
 435337-37-4P 435337-39-6P 435337-41-0P
 435337-43-2P 435337-45-4P 435337-47-6P
 435337-49-8P 435337-51-2P 435337-53-4P
 435337-55-6P 435337-57-8P 435337-59-0P
 435337-61-4P 435337-62-5P 435337-64-7P
 435337-66-9P 435339-57-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)


RN 435337-10-3 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indenolo[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)



RN 435337-11-4 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indenolo[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
 CRN 435337-10-3
 CMF C27 H26 N8 O2

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 435337-13-6 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 435337-14-7 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-trifluoroacetate (9CI) (CA INDEX NAME)

CM 1
 CRN 435337-13-6
 CMF C28 H28 N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2


L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-16-9 CAPLUS
 CN Hydrazinecarboxamide, N-[3-[4-(hexahydro-1H-1,4-diazepin-1-yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)




RN 435337-18-1 CAPLUS
 CN Hydrazinecarboxamide, N-[3-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)



L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 435337-20-5 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(4-pyridinyl)-(9CI) (CA INDEX NAME)




RN 435337-22-7 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-pyrazinyl- (9CI) (CA INDEX NAME)




RN 435337-24-9 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-26-1 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 435337-28-3 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-30-7 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-pyrazinyl- (9CI) (CA INDEX NAME)




RN 435337-32-9 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 435337-34-1 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 435337-36-3 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

10820453C>


07/08/2007

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 435337-37-4 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 435337-36-3
CMF C27 H31 N7 O3

CM 2


L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CRN 76-05-1
CMF C2 H F3 O2

RN 435337-39-6 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(1-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 435337-41-0 CAPLUS
CN Hydrazinecarboxamide, N-[3-[4-(4-ethyl-1-piperazinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-43-2 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-(1-methylethyl)-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 435337-45-4 CAPLUS
CN Hydrazinecarboxamide, 2-cyclohexyl-N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-47-6 CAPLUS
CN Hydrazinecarboxamide, 2-cyclohexyl-N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 435337-49-8 CAPLUS
CN Hydrazinecarboxamide, 2-cyclohexyl-N-[3-[4-(4-ethyl-1-piperazinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-51-2 CAPLUS
CN Hydrazinecarboxamide,
2-cyclohexyl-N-[2,4-dihydro-3-[4-(4-(1-methylethyl)-
1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl- (9CI)
(CA INDEX NAME)




RN 435337-53-4 CAPLUS
CN Hydrazinecarboxamide,
N-[3-[4-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)phenyl]-2,4-
dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-
yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-55-6 CAPLUS
CN Hydrazinecarboxamide, N-[3-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-
yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-
(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 435337-57-8 CAPLUS
CN Hydrazinecarboxamide, N-[3-[4-(4-ethylhexahydro-1H-1,4-diazepin-1-
yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-
(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-59-0 CAPLUS
CN Hydrazinecarboxamide,
N-[3-[4-(4-ethylhexahydro-1H-1,4-diazepin-1-
yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-
(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 435337-61-4 CAPLUS
CN Hydrazinecarboxamide,
N-[3-[4-(dimethylaminol-1-piperidinyl)phenyl]-2,4-
dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-
yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 435337-62-5 CAPLUS
CN Hydrazinecarboxamide,
N-[3-[4-(dimethylaminol-1-piperidinyl)phenyl]-2,4-
dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-
yl)- acetate (9CI) (CA INDEX NAME)

CM 1

CRN 435337-61-4
CMF C30 H37 N7 O3


CM 2

CRN 64-19-7
CMF C2 H4 O2

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435337-64-7 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 435337-66-9 CAPLUS
CN Hydrazinecarboxamide, N-[3-(4-(1,4'-bipiperidinyl)-1'-ylphenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 435339-57-4 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




IT 435337-70-5P 435337-72-7P 435337-80-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 435337-70-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[2,4-dihydro-5-[(2-methyl-2-(2-pyridinyl)hydrazino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 435337-72-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[2,4-dihydro-5-[(2-methyl-2-(tetrahydro-2H-pyran-4-yl)hydrazino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L12 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

RN 435337-80-7 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(4-oxo-1-piperidinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-2-methyl-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:731369 CAPLUS
 DOCUMENT NUMBER: 135:288778
 TITLE: Preparation of indeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin dependent kinases
 INVENTOR(S): Nugiel, David A.; Carini, David J.; Dimeo, Susan V.; Yue, Eddy W.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of U.S. Ser. No. 639,618.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001027195	A1	20011004	US 2000-731304	20001206
US 6407103	B2	20020618		
US 6413957	B1	20020702	US 2000-639618	20000815
CA 2420164	A1	20020502	CA 2000-2420164	20001020
AU 200112168	A	20020506	AU 2001-12168	20001020
EP 1414804	A1	20040506	EP 2000-973682	20001020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2004524277	T	20040812	JP 2002-537713	20001020
US 1998-62476P P 19980421				
US 1999-295078 B1 19990420				
US 2000-639618 A2 20000815				
WO 2000-US28952 W 20001020				

OTHER SOURCE(S): MARPAT 135:288778
 GI



AB: The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula [X = O, S, (un)substituted NH; R1 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, NH2, C3-10

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 membered carbocyclc, 3-10 membered heterocycle contg. 1-4 heteroatoms selected from O, N, and S; R2 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, (CF2)mCF3, C3-10 membered carbocyclc, 3-10 membered heterocycle contg. 1-4 heteroatoms selected from O, N, and S; wherein m = 0, 1-4). These compds. are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits known as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amt. of one of these compds. or a pharmaceutically acceptable salt form thereof. Alternatively, cancer or other proliferative diseases can be treated by administering a therapeutically effective combination of one

of the compds. of the present invention and one or more other known anti-cancer or anti-proliferative agents (no date). Thus, hydrogenation of di-Me 3-nitrophthalate over 5% Pd-C in methanol in a Parr shaker at 50 psi for 2 h followed by acetylation with Ac2O in pyridine at 25° for 2 h gave 79% di-Me 3-acetamidophthalate which was treated with NaH in DMF and cyclocondensed with 4-methoxyacetophenone at 90° for 20 min to give 30% 2-(4-methoxybenzoyl)-4-acetamidoindane-2,3-dione.

Cyclocondensation of the latter triketone with hydrazine hydrate in the presence of p-TsOH in ethanol under reflux for 2 h gave I (R1 = Me, X =


O, R2 = 4-methoxyphenyl).

IT 247149-81-8P 247149-83-OP 247149-02-6P
 247149-03-7P 247149-04-8P 247149-05-9P
 247149-06-0P 247149-85-5P 247149-86-6P
 247149-87-7P 247149-88-0P 247149-90-2P
 247149-92-4P 247149-93-5P 247149-94-6P
 247150-88-5P 364733-85-7P 364733-87-9P
 364734-01-0P 364734-74-7P 364734-75-8P
 364734-76-9P 364734-77-0P 364734-78-1P
 364734-79-2P 364734-80-6P 364734-81-6P
 364734-82-7P 364734-83-8P 364734-84-9P
 364734-85-0P 364734-87-2P 364734-88-3P
 364734-90-7P 364734-91-6P 364734-93-0P
 364734-95-2P 364734-96-3P 364734-98-5P
 364735-00-2P 364735-01-3P 364735-02-4P
 364735-03-5P 364735-05-7P 364735-06-8P
 364735-07-9P 364735-09-1P 364735-10-4P
 364735-11-5P 364735-12-6P 364735-13-7P
 364735-14-8P 364735-78-4P


R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of indeno[c]pyrazolones as inhibitors of cyclin dependent kinases)

RN 247149-81-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247148-83-0 CAPLUS
 CN Urea, N-[4-aminophenylmethyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (CA INDEX NAME)




RN 247149-02-6 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (CA INDEX NAME)




RN 247149-03-7 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-04-8 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 247149-05-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 247149-06-0 CAPLUS
 CN Urea, N-[(1R,2S)-2-aminocyclohexyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-85-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 247149-86-6 CAPLUS
CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-87-7 CAPLUS
CN Urea,
[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 247149-88-8 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 247149-90-2 CAPLUS
CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
5-yl]-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

RN 247149-92-4 CAPLUS
CN Urea,
N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247149-93-5 CAPLUS
CN Urea, N-[3-(4-(4-ethyl-1-piperazinyl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-94-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-(4-methylethyl)-1-piperazinyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247150-88-5 CAPLUS
CN Urea,
N-[3-(4-(dimethylamino)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-methyl-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 364733-85-7 CAPLUS
CN Urea, N-butyl-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-(CA INDEX NAME)




RN 364733-87-9 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-pyridinyl-(9CI) (CA INDEX NAME)




RN 364734-01-0 CAPLUS
CN Urea, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperidinyl)-(9CI) (CA INDEX NAME)




RN 364734-74-7 CAPLUS
CN Hydrazinecarboxamide, N-(2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)-2,2-dimethyl-(9CI) (CA INDEX NAME)




RN 364734-75-8 CAPLUS
CN Hydrazinecarboxamide, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl-(9CI) (CA INDEX NAME)




RN 364734-76-9 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)



RN 364734-77-0 CAPLUS
CN Urea, N-[3-[4-(4-ethyl-1-piperazinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)




RN 364734-78-1 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)-(9CI) (CA INDEX NAME)




RN 364734-79-2 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2,6-dimethyl-1-piperidinyl)-(9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 364734-80-5 CAPLUS


CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(4-(2-hydroxyethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)

RN 364734-81-6 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2R)-2-(methoxymethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 364734-82-7 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2S)-2-(methoxymethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364734-83-8 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2R)-2-(1-methoxy-1-methylethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 364734-84-9 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2R)-2-(2-methoxy-1-methylethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364734-85-0 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2R)-2-(hydroxymethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 364734-87-2 CAPLUS

CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2S)-2-(hydroxymethyl)-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 364734-88-3 CAPLUS


CN Urea,
N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-(2R)-2-[(phenylmethoxy)methyl]-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364734-90-7 CAPLUS
CN Urea,
N-[2,4-dihydro-4-oxo-3-[(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-(2S)-2-[(phenylmethoxy)methyl]-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364734-91-8 CAPLUS
CN Urea,
N-[2,4-dihydro-3-[(3-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364734-93-0 CAPLUS
CN Urea, N-[3-[(3R,5S)-3,5-dimethyl-1-piperazinyl]phenyl]-2,4-dihydro-4-oxindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 364734-95-2 CAPLUS
CN Urea, N-[2,4-dihydro-4-oxo-3-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 364734-96-3 CAPLUS
CN Urea, N-[2,4-dihydro-3-[(2-methyl-4-[(1-methylethyl)-1-piperazinyl]phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364734-98-5 CAPLUS
CN Urea, N-[3-[(4-(hexahydro-1H-1,4-diazepin-1-yl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-00-2 CAPLUS
CN Urea,
N-[3-[(4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-01-3 CAPLUS
CN Urea,
N-[3-[(4-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)phenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-02-4 CAPLUS
 CN Urea, N-[3-[4-(hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-03-5 CAPLUS
 CN Urea, N-[3-[4-(hexahydro-1H-1,4-diazepin-1-yl)-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-05-7 CAPLUS
 CN Urea, N-[3-[4-(4-ethylhexahydro-1H-1,4-diazepin-1-yl)-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-06-8 CAPLUS
 CN Urea, N-[3-[4-(hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl)-2-methylphenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-07-9 CAPLUS
 CN Urea, N-[3-[4-(dimethylamino)-1-piperidinyl]phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 364735-09-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-(4-morpholinyl)-1-piperidinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-10-4 CAPLUS
 CN Urea, N-[3-(4-(1,4'-bipiperidin)-1'-ylphenyl)-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-11-5 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-(4-(1-pyrrolidinyl)-1-piperidinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 364735-12-6 CAPLUS
 CN Urea, N-[3-[4-(4-(diethylamino)-1-piperidinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 364735-13-7 CAPLUS
 CN Piperazine, 1-[4-(2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino)-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 364735-14-8 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(4-(2-pyridinyl)-1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



RN 364735-78-4 CAPLUS
 CN Urea,
 N-(2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)-N'-(2S)-2-(1-methoxy-1-methylethyl)-1-pyrrolidinyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 364735-93-3P 364735-94-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indeno[c]pyrazolones as inhibitors of cyclin dependent kinases)
 RN 364735-93-3 CAPLUS
 CN Urea, N-[3-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 364735-94-4 CAPLUS
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-(4-oxo-1-piperidinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:687444 CAPLUS
 DOCUMENT NUMBER: 135:242226
 TITLE: Preparation of a new acylsemicarbazide-containing
 indeno[1,2-c]pyrazol-4-ones as cyclin dependent
 kinase inhibitors
 INVENTOR(S): Nugiel, David A.; Carini, David J.; Di Meo, Susan V.;
 Vidwans, Anup P.; Yue, Eddy W.
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, USA
 SOURCE: U.S., 26 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6291504	B1	20010918	US 2000-692023	20001019
US 2003073686	A1	20030417	US 2001-906963	20010716
US 6593156	B2	20030715		
US 2004048844	A1	20040311	US 2003-427540	20030501
US 2005261353	A1	20051124	US 2005-64758	20050224
PRIORITY APPLN. INFO.:			US 1999-160713P	P 19991020
			US 2000-692023	A2 20001019
			US 2001-906963	A2 20010716
			US 2003-427540	B1 20030501

OTHER SOURCE(S): MARPAT 135:242226
 GI



AB The title compds. [I; X = O, S; R1 = NR3R3a, CF3, alkyl, etc.; R2 = H, alkyl, alkenyl, etc.; R3, R3a = H, alkyl, Ph, CH2Ph; R5 = H, alkyl, Ph, etc.] that are potent inhibitors of the class of enzymes known as cyclin dependent kinases which relate to the catalytic subunits cdk1-9 and their regulatory subunits known as cyclins A-H (no biol. data given), and are useful in treating cancer or other proliferative diseases, were prepared e.g., a 3-step synthesis of I [X = O; R1 = 3,5-(MeO)2C6H3; R2 = 4-MeOC6H4];

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 360792-67-2P 360792-68-3P 360792-69-4P
 360792-70-7P 360792-71-8P 360792-72-9P
 360792-73-OP 360792-74-1P 360792-75-2P
 360792-76-3P 360792-77-4P 360792-78-5P
 360792-79-6P 360792-80-9P 360792-81-OP
 360792-83-2P 360792-84-3P 360792-85-4P
 360792-86-5P 360792-87-6P 360792-88-7P
 360792-89-8P 360792-90-1P 360792-91-2P
 360792-92-3P 360792-94-5P 360792-95-6P
 360792-96-7P 360792-98-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of a new acylsemicarbazide-containing indeno[1,2-c]pyrazol-4-ones as cyclin dependent kinase (cdk) inhibitors)


RN 360792-67-2 CAPLUS
 CN Benzoic acid, 3,5-dimethoxy-, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 R5 = H was given. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compds. I and one or more other known anti-cancer or anti-proliferative agents.
 IT 360792-93-4P 360792-97-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of a new acylsemicarbazide-containing indeno[1,2-c]pyrazol-4-ones as cyclin dependent kinase (cdk) inhibitors)

RN 360792-93-4 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 360792-92-3
 CMF C27 H24 N8 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-69-4 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-69-4 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-70-7 CAPLUS
 CN Benzoic acid, 3,4-dihydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-71-8 CAPLUS
 CN Benzoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-72-9 CAPLUS
 CN Benzoic acid, 3-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-73-0 CAPLUS
 CN Benzoic acid, 4-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-74-1 CAPLUS
 CN Benzoic acid, 2-amino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-75-2 CAPLUS
 CN Benzoic acid, 4-(dimethylamino)-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-76-3 CAPLUS
 CN Benzoic acid, 2-methoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-77-4 CAPLUS
 CN Benzoic acid, 2-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-78-5 CAPLUS
 CN Benzoic acid, 3,5-diamino-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-79-6 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (9CI) (CA INDEX NAME)


L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 360792-80-9 CAPLUS
 CN 1,2-Hydrazinedicarboxamide, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 360792-81-0 CAPLUS
 CN 1,2-Hydrazinedicarboxamide, N-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 360792-83-2 CAPLUS
 CN Benzoic acid, 4-methyl-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-



L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



RN 360792-84-3 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-85-4 CAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)




RN 360792-86-5 CAPLUS
 CN Benzoic acid, 4-methoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonylhydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-87-6 CAPLUS
 CN Benzoic acid, 3-nitro-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-88-7 CAPLUS
 CN Benzoic acid, 3,4,5-trimethoxy-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-91-2 CAPLUS
 CN Benzoic acid, 2,5-dichloro-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)




RN 360792-92-3 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-89-8 CAPLUS
 CN 2-Thiophenecarboxylic acid, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 360792-90-1 CAPLUS
 CN Benzoic acid, 3-methyl-, 2-[(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (CA INDEX NAME)

L12 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 360792-94-5 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-(4-(4-methyl-1-piperazinyl)phenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 360792-95-6 CAPLUS
 CN 3-Pyridinecarboxylic acid, 2-[(2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)amino]carbonyl]hydrazide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 360792-94-5
 CMF C28 H26 N8 O3



CM 2



CRN 76-05-1
CMF C2 H P3 O2

RN 360792-96-7 CAPLUS
 CN 4-Pyridinecarboxylic acid, 2-[[2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 360792-98-9 CAPLUS


CN Benzoic acid, 3,5-dimethoxy-, 2-[[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]amino]carbonyl]hydrazide (9CI) (CA INDEX NAME)



IT 360793-06-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of a new acylsemicarbazide-containing indeno[1,2-c]pyrazole-4-ones)

RN 360793-06-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-dihydro-4-oxo-5-[[2-(3-pyridinyl)carbonyl]hydrazino]carbonyl)amino]indeno[1,2-c]pyrazol-3-ylphenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999-691083 CAPLUS

DOCUMENT NUMBER: 131:299444

TITLE: Preparation of 5-aminoindeno[1,2-c]pyrazole-4-ones as

anti-cancer and anti-proliferative agents

INVENTOR(S): Nugiel, David A.; Carini, David J.; Yue, Eddy W.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954308	A1	19991028	WO 1999-US8616	19990420
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KE, MD, RU, TJ,				
TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9909597	A	20011002	BR 1999-9597	19990420
JP 200251230	T	20020423	JP 2000-544647	19990420
NZ 507567	A	20030829	NZ 1999-507567	19990420
ZA 2000004445	A	20010828	ZA 2000-4445	200000828
MX 2000PA10299	A	20010405	MX 2000-PA10299	200001020
CA 2420164	A1	20020502	CA 2000-2420164	200001020
WO 2002034721	A1	20020502	WO 2000-US28952	200001020
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KE, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AU 200112168	A	20020506	AU 2001-12168	200001020
EP 1414804	A1	20040506	EP 2000-973682	19990420
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2004524277	T	20040812	JP 2002-537713	200001020
PRIORITY APPLN. INFO.: US 1998-824769				
OTHER SOURCE(S): MARPAT 131:299444				
GI				
WO 1999-US8616				
WO 2000-US28952				



AB The title compds. (I; X = O, S, NR (wherein R = H, alkyl, (un)substituted NH₂); R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.) that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G and therefore are useful in treating cancer or other proliferative diseases (no data), were prepared. E.g., a 3-step synthesis of indeno[1,2-c]pyrazol-4-one II, starting with di-Me 3-nitrophthalate, was given. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compds. I and one or more other known anti-cancer or anti-proliferative agents.

IT 247149-85-5P 247149-86-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 5-aminoindeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)

RN 247149-85-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[2,4-dihydro-5-[(4-morpholinylamino)carbonyl]amino]-4-oxoindeno[1,2-c]pyrazol-3-yl]phenyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 247149-81-8 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-phenyl- (CA INDEX NAME)




RN 247149-82-9 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-propyl- (9CI) (CA INDEX NAME)




RN 247149-83-0 CAPLUS

CN Urea, N-[(4-aminophenyl)methyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 247149-84-1 CAPLUS

SAEED



RN 247149-86-6 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-(1-piperazinyl)phenyl)indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)



IT 247149-81-8P 247149-82-9P 247149-83-0P

247149-84-1P 247149-02-6P 247149-03-7P

247149-04-8P 247149-05-9P 247149-06-0P

247149-07-1P 247149-07-7P 247149-08-0P


247149-09-2P 247149-09-3P 247149-09-4P

247149-09-5P 247149-09-6P 247149-08-5P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 5-aminoindeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents)

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 247149-02-6 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]- (CA INDEX NAME)



RN 247149-03-7 CAPLUS


CN Hydrazinecarboxamide, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-2,2-dimethyl- (CA INDEX NAME)




RN 247149-04-8 CAPLUS

CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-methyl- (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-05-9 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




RN 247149-06-0 CAPLUS
 CN Urea,
 N-[(1R,2S)-2-aminocyclohexyl]-N'-(2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-90-2 CAPLUS
 CN Urea,
 N-(2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)-N'-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 247149-91-3 CAPLUS
 CN Urea, N-(4-(aminomethyl)-1-piperidinyl)-N'-(2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl)- (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 247149-07-1 CAPLUS
 CN Urea, N-[2,4-dihydro-3-(4-methoxyphenyl)-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 247149-87-7 CAPLUS
 CN Urea,
 [2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 247149-88-8 CAPLUS
 CN Hydrazinecarboxamide, N-[2,4-dihydro-4-oxo-3-[4-(1-piperazinyl)phenyl]indeno[1,2-c]pyrazol-5-yl]- (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 247149-92-4 CAPLUS
 CN Urea,
 N-(2,4-dihydro-3-[4-(4-methyl-1-piperazinyl)phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl)-N'-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 247149-93-5 CAPLUS
 CN Urea, N-[3-[4-(4-ethyl-1-piperazinyl)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

10820453C>


07/08/2007

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 247149-94-6 CAPLUS
CN Urea, N-[2,4-dihydro-3-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (9CI) (CA INDEX NAME)

L12 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT



RN 247150-88-5 CAPLUS
CN Urea,
N-[3-[4-(dimethylamino)phenyl]-2,4-dihydro-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-[4-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

10820453C>

07/08/2007

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

101.07	620.28
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

CA SUBSCRIBER PRICE

-14.82	-14.82
--------	--------

STN INTERNATIONAL LOGOFF AT 10:54:55 ON 08 JUL 2007